Class-switch DNA recombination (CSR) and somatic hypermutation (SHM), which require activation-induced cytidine deaminase (AID), and plasma cell differentiation, which requires B lymphocyte–induced maturation protein-1 (Blimp-1), are critical for the generation of class-switched and hypermutated (mature) Ab and autoantibody responses. We show that histone deacetylase inhibitors valproic acid and butyrate dampened AICDA/Aicda (AID) and PRDM1/Prdm1 (Blimp-1) mRNAs by upregulating miR-155, miR-181b, and miR-361 to silence AICDA/Aicda, and miR-23b, miR-30a, and miR-125b to silence PRDM1/Prdm1, in human and mouse B cells. This led to downregulation of AID, Blimp-1, and X-box binding protein 1, thereby inhibiting CSR, SHM, and plasma cell differentiation without altering B cell viability or proliferation. The selectivity of histone deacetylase inhibitor–mediated silencing of AICDA/Aicda and PRDM1/Prdm1 was emphasized by unchanged expression of HoxC4 and Irf4 (important inducers/modulators of AICDA/Aicda), Rev1 and Ung (central elements for CSR/SHM), and Bcl6, Bach2, or Pax5 (repressors of PRDM1/Prdm1 expression), as well as unchanged expression of miR-19a/b, miR-20a, and miR-25, which are not known to regulate AICDA/Aicda or PRDM1/Prdm1. Through these B cell–intrinsic epigenetic mechanisms, valproic acid blunted class-switched and hypermutated T-dependent and T-independent Ab responses in C57BL/6 mice. In addition, it decreased class-switched and hypermutated autoantibodies, ameliorated disease, and extended survival in lupus MRL/Faslpr/lpr mice. Our findings outline epigenetic mechanisms that modulate expression of an enzyme (AID) and transcription factors (Blimp-1 and X-box binding protein 1) that are critical to the B cell differentiation processes that underpin Ab and autoantibody responses. They also provide therapeutic proof-of-principle in autoantibody-mediated autoimmunity.

Immunoglobulin class-switch DNA recombination (CSR) and somatic hypermutation (SHM) are critical for the production of protective Abs against microbial pathogens, IgE in allergic responses, as well as pathogenic autoantibodies in autoimmune diseases. CSR recombines S-region DNA located upstream of exons of constant H chain (CH) regions, thereby encoding new Ig CH regions that endow Abs with new biological effector functions (1). SHM introduces mainly point mutations in Ig-variable regions, thereby providing the structural substrate for Ag-mediated selection of B cell mutants with higher-affinity BCRs (2, 3). CSR and SHM require activation-induced cytidine deaminase (AID; encoded by Aicda in mice and AICDA in humans), which is expressed in a B cell–differentiation stage-specific fashion (1, 2). Class-switched and hypermutated B cells further differentiate into Ab-secreting plasma cells in a fashion critically dependent on B lymphocyte–induced maturation protein 1 (Blimp-1; encoded by Prdm1 in mice and PRDM1 in humans) (4).

As a potent DNA mutator, AID must be tightly regulated to prevent off-target effects, which may result in mutations in non-Ig genes, genomic instability, and interchromosomal translocations (5, 6). Accordingly, AID is expressed in B cells and in a B cell–differentiation stage-specific fashion. This is made possible by stringent transcriptional, posttranscriptional, and posttranslational control (2). In response to T-dependent and T-independent “primary” stimuli (e.g., CD154, LPS, BAFF, and APRIL) (710), AID expression is induced by multiple transcription factors, including HoxC4, NF-κB, Pax5, Irf4, Irf8, Oct1/Oct2, Sp1/Sp3, and E47 (2, 1114). AID expression is further upregulated by secondary stimuli (e.g., IL-4, TGF-β, or IFN-γ), which induce selected intervening region (IH)–S-CH germline transcription, thereby directing CSR to specific isotypes (1, 15). It is then downregulated in memory B cells and plasma cells to preserve the specificity, affinity, and isotype of the expressed BCR and Ab (1, 2). Terminal plasma cell differentiation is critically dependent on the transcriptional repressor Blimp-1. This extinguishes the proliferative mature B cell gene-expression program and drives the expression of X-box–binding protein 1 (Xbp-1), which induces secretory pathway genes for Ig secretion (4, 16, 17).

As we contended, an additional and critical level of regulation of AID expression would occur through epigenetic modifications and factors (2, 3, 18). As we also contended, epigenetic modifications and factors, including histone posttranslational modifications, DNA methylation, and microRNAs (miRNAs), interact with genetic programs to regulate B cell CSR, SHM, and plasma cell differentiation, thereby informing the Ab response (3). Accordingly, we suggested that, in addition to DNA methylation of the Aicda promoter (19) and histone acetylation of the Aicda locus (20), selected miRNAs provide a more important mechanism of modulation of AID expression (2, 3, 18). miRNAs likely play important roles in B cell development and peripheral differentiation, as well as T cell stage-specific differentiation and autoimmunity (18, 2126). Some miRNAs, including miR-155, miR-181b, and miR-361, would negatively regulate AID expression (2, 2730), whereas miR-30a (31) and miR-125b (32, 33) would negatively regulate Blimp-1 expression. These miRNAs bind to evolutionarily conserved miRNA target sites in the 3′ untranslated region (UTR) of Aicda and Prdm1 mRNAs and cause degradation of the mRNA transcripts and/or inhibit their translation.

Histone deacetylase (HDAC) inhibitors (HDIs) were shown to alter gene expression by altering chromatin accessibility (3437). In immune cells, these epigenetic modifiers exert modulatory effects, even at moderate concentrations. By using two well-characterized short-chain fatty acid (SCFA) HDIs, valproic acid (VPA) or sodium valproate (2-propyl-pentanoic acid sodium) (38) and sodium butyrate (butyrate) (39), we tested the hypothesis that HDIs regulate intrinsic B cell functions that are critical in shaping effective Ab and autoantibody responses. VPA is a U.S. Food and Drug Administration–approved drug, which, as marketed under different brand names, is widely used as an anticonvulsant and a mood stabilizer. It selectively inhibits class I HDACs, particularly HDAC1 and HDAC2, and, less effectively, class IIa HDACs, of the four HDAC classes identified in mammals (38, 40). Butyrate is a major metabolite in the digestive tract, arising from bacterial fermentation of dietary fibers (41, 42), and it is widely available as a dietary supplement. Butyrate modulates gene expression by selectively inhibiting HDAC1, and, less effectively, other members of class I and class IIa HDACs (39).

We addressed the ability of VPA and butyrate to modulate AID and Blimp-1 expression, CSR, SHM, and plasma cell differentiation in human and mouse B cells in vivo and in vitro. In addition, we analyzed the role of HDIs as epigenetic modifiers of selected B cell miRNAs that silence Aicda and Prdm1 in Ab and autoantibody responses. Finally, we evaluated the impact of VPA on NP-CGG and NP-LPS class-switched and hypermutated Ab responses in normal mice, as well as on the autoantibody response in lupus-prone MRL/Faslpr/lpr mice. Our findings outline important modalities of epigenetic regulation of AID and Blimp-1 expression, unveil new approaches to modulation of T-dependent and T-independent Ab responses, and provide a proof-of-principle therapeutics study in autoantibody-mediated autoimmunity.

For in vivo studies, VPA sodium salt (Sigma-Aldrich) was dissolved in drinking water at 0.8% w/v. This yields a stable VPA serum level (400–600 μM) in mice, comparable to the serum concentration in humans under long-term VPA treatment (300–900 μM) (43, 44). Drinking water containing VPA at the above concentration (HDI water) was always well accepted by C57BL/6 and MRL/Faslpr/lpr mice. VPA and butyrate (obtained as sodium butyrate from Sigma-Aldrich) were directly diluted in culture media for in vitro experiments, at molarities ranging from 125 to 1000 μM. trichostatin A (TSA; Cayman Chemical) was dissolved in DMSO and diluted in culture media at 10 or 20 nM (∼3 or 6 ng/ml) for in vitro experiments.

C57BL/6 mice (The Jackson Laboratory) were housed in a pathogen-free vivarium and provided with autoclaved food and deionized water. To study the T-dependent Ab response, 16 8-wk-old C57BL/6 mice received an i.p. injection of 100 μg NP16-CGG (Biosearch Technologies) in alum (Imject alum; Pierce). Eight of the sixteen mice were on HDI water ad libitum, starting the day before and continuing throughout the duration of the experiment. The remaining eight mice were given untreated drinking water. Five mice drinking HDI water and five mice drinking untreated water were sacrificed at day 10; the remaining six mice were given a “booster” i.p. injection of 100 μg NP16-CGG (Biosearch Technologies) in alum at day 21 and were sacrificed at day 28. To study the T-independent Ab response, eight 8-wk-old C57BL/6 mice received an i.p. injection of 25 μg NP-LPS (Biosearch Technologies) in PBS. Four of these mice were on HDI water and four received untreated water throughout the duration of the experiment. All eight mice were given a “booster” injection of 25 μg NP-LPS at day 21 and were sacrificed at day 28. The Institutional Animal Care and Use Committees of the University of California, Irvine and the UT Health Science Center, San Antonio approved all animal protocols.

Naive IgD+ B cells were isolated from 8- to 12-wk-old C57BL/6 mice, as described (9). B cells were resuspended in RPMI 1640 medium with 10% FBS, 50 mM 2-ME, and 1× antibiotic-antimycotic mixture (15240-062; Invitrogen) (FBS-RPMI) at 37°C in 48-well plates and stimulated with LPS (5 μg/ml) from Escherichia coli (055:B5; Sigma-Aldrich) for CSR to IgG3; LPS (3 μg/ml) or CD154 [1 U/ml; obtained from membrane fragments of baculovirus-infected Sf21 insect cells (45)] + IL-4 (5 ng/ml; R&D Systems) for CSR to IgG1/IgE and plasma cell differentiation; or LPS (3 μg/ml) or CD154 (1 U/ml) + TGF-β (2 ng/ml; R&D Systems), IL-4 (5 ng/ml), IL-5 (3 ng/ml; R&D Systems), and anti-IgD dextran-Ab (Fina Biosolutions) for CSR to IgA. Nil, VPA [125–1000 μM; doses that were similar to or below serum concentrations of VPA-treated mice (46)], or butyrate (125–1000 μM) was added to cultures, and cells or supernatants were collected at various times.

Human naive IgD+ B cells (>95% pure) were purified by negative selection, using the EasySep Human Naive B Cell Enrichment Kit (19254; STEMCELL Technologies), from healthy donor PBMCs, following the manufacturer’s instructions. Naive B cells were then cultured in FBS-RPMI and stimulated with CD154 (10 U/ml), IL-4 (20 ng/ml; R&D Systems) and IL-21 (50 ng/ml; R&D Systems) or CD154 (10 U/ml), IL-21 (50 ng/ml), and TGF-β (0.5 ng/ml) in the presence of nil, VPA, or butyrate for 120 h. B cells were then stained with 7-aminoactinomycin D (7-AAD), FITC–anti-IgM mAb (F5384; Sigma-Aldrich), PE–anti-CD19 mAb (HIB19; BioLegend), and allophycocyanin–anti-IgG mAb (G18-145; BD Biosciences) or 7-AAD, FITC–anti-IgA mAb (F5259; Sigma-Aldrich), PE–anti-CD19 mAb (HIB19; BioLegend), and biotin-F(ab′)2 anti-IgM (2022-08; Southern Biotech), followed by allophycocyanin-streptavidin, and analyzed by flow cytometry. For plasma cell differentiation, cells were stained with 7-AAD (BD Biosciences), allophycocyanin–anti-CD27 (LG.3A10; BioLegend), and FITC–anti-CD38 (31014X; BD Biosciences) and analyzed by flow cytometry.

For surface staining, B cells were reacted with PE–anti-B220 mAb (CD45R; RA3-6B2; eBioscience), Alexa Fluor 647–peanut agglutinin (PNA; Invitrogen), PE–anti-IgM mAb (AF6-78; BD Biosciences), FITC–anti-IgG1 mAb (A85-1; BD Biosciences), FITC–anti-IgG3 mAb (R40-82; BD Biosciences), FITC–anti-IgA mAb (C10-3; BD Biosciences), 7-AAD, and biotin–anti-CD138 mAb (281-2; BD Biosciences), followed by FITC-streptavidin (11-4317-87; eBioscience) or PE-streptavidin (12-4317-87; eBioscience), FITC–anti-CD3 mAb (17A2; BioLegend), FITC–anti-CD4 (GK1.5; BioLegend), and/or allophycocyanin–anti-CD8 mAb (53-6.7; BD Biosciences). For intracellular staining, B cells were fixed in 150 μl formaldehyde (3.6%) for 10 min at 25°C. In the case of IgE intracellular staining, cells were trypsinized and then fixed (47). Cells were then permeabilized in cold methanol (90%) for 30 min on ice before staining with biotin–anti-CD138 mAb, followed by PE-streptavidin, PE-Cy7–anti-B220 mAb (RA3-6B2; eBioscience), FITC–anti-IgM mAb (II/41; BD Biosciences), allophycocyanin–anti-IgG1 mAb (A85-1; BD Biosciences), and/or PE–anti-IgE mAb (23G3; eBioscience). FACS was performed on single spleen cell suspensions. Cells were surface stained with PE–anti-CD19 (1D3; BD Biosciences), 7-AAD, and biotin–anti-CD138, followed by FITC-streptavidin. CD19+CD138 B cells (consisting of a large proportion of germinal center [GC] B cells, referred to as “total” B cells) and CD19loCD138+ plasma cells were then sorted using a Cytomation MoFlo cell sorter (Beckman Coulter) and frozen at −80°C until used for gene-expression analysis. Annexin V analysis for apoptotic cells was performed using the Annexin V:FITC Apoptosis Detection Kit II (556570; BD Biosciences), according to the manufacturer’s protocol. In all flow cytometry experiments, cells were appropriately gated on forward scatter and side scatter to exclude dead cells and debris. Cell analyses were performed using a FACSCalibur flow cytometer (BD Biosciences), and data were analyzed using FlowJo software (TreeStar). All experiments were performed in triplicate.

To analyze C57BL/6 B cell proliferation in vivo, mice previously injected i.p. with NP16-CGG were injected i.p. 10 d later (twice within 16 h) with BrdU (1 mg) and sacrificed 4 h after the last injection. For in vivo MRL/Faslpr/lpr B cell proliferation, mice were provided with drinking water containing BrdU (0.8 mg/ml) for 10 d before sacrifice. Spleen cells were stained with PE–anti-B220 mAb. Incorporated (intracellular) BrdU was stained with allophycocyanin–anti-BrdU mAb using the APC BrdU Flow Kit (BD Biosciences) and analyzed by flow cytometry, and the B cell cycle was analyzed with the same kit, according to the manufacturer’s instructions. Briefly, spleen B cells were stimulated and cultured as previously described, except that the cells were pulse-labeled with 10 μM BrdU during the last 30 min of culture. The cells were then stained with PE–anti-B220 mAb before being fixed/permeabilized and stained for total DNA content with 7-AAD and BrdU incorporation with allophycocyanin–anti-BrdU mAb. B cell division was analyzed by CFSE dilution using the CellTrace CFSE Cell Proliferation Kit (Invitrogen). Briefly, B cells were incubated for 3 min at 37°C in 1 ml PBS with 2.5 μM CFSE at a density of 1 × 106 cells/ml and then washed in FBS-RPMI. Cells were cultured in the presence of LPS alone or LPS + IL-4 for 4 d before being stained with PE–anti-B220 mAb, 7-AAD, and allophycocyanin–anti-IgG1 mAb (X56; BD Biosciences) or biotin–anti-IgG3 mAb (R40-82; BD Biosciences), followed by allophycocyanin-streptavidin (554067; BD Biosciences), and subsequently were analyzed by flow cytometry.

Titers of IgG1, IgG3, IgA, and IgE in cell culture supernatants of in vitro–stimulated B cells or in vivo titers of circulating total and/or NP-binding IgM, IgG1, IgG2b, and IgG3 were measured using specific ELISAs, as we described (12, 14, 48). Titers of NP30- or NP3-binding IgM, IgG1, and IgG3 also were determined, as previously described (12, 14, 48), and expressed as relative units (RU), defined as the dilution factor needed to reach 50% saturation binding, as calculated using GraphPad Prism software (GraphPad). ELISAs for human Ig were performed as previously described (12, 14, 48), except that plates were coated with F(ab′)2 anti-Ig (H+L) Ab (2012-01), and Ig were detected by biotin-rabbit F(ab′)2 anti-IgG (2042-08) or biotin-rabbit F(ab′)2 anti-IgA (2052-08; all from Southern Biotech).

MultiScreen ELISPOT plates (MAIPS4510; Millipore) were activated with ethanol (35%), washed four times with PBS, and coated with 100 μl NP3-BSA (5 μg/ml; N-5050L; Biosearch Technologies) in PBS overnight at 4°C. The plates were then washed six times with PBS and blocked with BSA (0.5%) in RPMI/HEPES + l-glutamine for 1 h at room temperature. Single-cell suspensions from spleens of NP-LPS–injected mice were cultured in the plates at 37°C for 16 h in FBS-RPMI at concentrations of 250,000, 125,000, and 75,000 cells/ml. The cultures were removed, and the plates were washed six times, incubated with biotin–anti-IgG3 (R40-82; BD Biosciences) for 2 h on a shaker at room temperature, washed, incubated with HRP-streptavidin (Santa Cruz Biotech) for 1 h on a shaker at room temperature, washed again, and developed using the VECTASTAIN AEC Peroxidase Substrate Kit, following manufacturer’s protocol (SK-4200; Vector Laboratories). Plates were imaged and quantified using a CTL-ImmunoSpot Analyzer and software (Cellular Technology Limited).

To analyze IgG1-producing cells, B cells stimulated with LPS + IL-4 were immobilized on acid-washed cover slips coated with poly-d-lysine. Cells were fixed with formaldehyde (3.6%) for 10 min at 25°C, washed three times with TBS, permeabilized with Triton X-100 (0.5%) in TBS for 10 min at 25°C, washed three times with Triton X-100 (0.1%) in TBS, and then stained with FITC–anti-IgG1 mAb and biotin–anti-CD138 mAb, followed by allophycocyanin-streptavidin or anti–Blimp-1 mAb (6D3; eBioscience), followed by Alexa Fluor 647–anti-IgG mAb (4418; Cell Signaling Technology) for 1 h at 25°C. After washing three times with Triton X-100 (0.1%) in TBS, cover slips were mounted with ProLong Gold Antifade Reagent with DAPI (Invitrogen). Fluorescent images were captured using a 40× objective lens with an Olympus FluoView FV1000 Laser Scanning Confocal microscope. To analyze GC structure, 8-μm spleen sections were prepared by cryostat and loaded onto positively charged slides, fixed in cold acetone, and stained with FITC-PNA and PE–anti-B220 mAb for 1 h at 25°C in a moist chamber. Cover slips were mounted using ProLong Gold Antifade Reagent with DAPI before examination using an Olympus CKX41 fluorescence microscope.

B cells from C57BL/6 mice were stimulated with LPS (5 μg/ml), LPS (3 μg/ml) + IL-4 (4 ng/ml), or CD154 (1 U/ml) + IL-4 (5 ng/ml) in the presence of nil, VPA (1000 μM), or butyrate (1000 μM) for 60 h. Cells were harvested and lysed in Laemmli buffer. Cell extracts containing equal amounts of protein (20 μg) were fractionated through SDS-PAGE (10%). The fractionated proteins were transferred onto polyvinylidene difluoride membranes (Bio-Rad) overnight (30 V) at 4°C. After blocking and overnight incubation at 4°C with anti-AID (ZA001; Invitrogen), anti–Blimp-1 mAb (6D3; eBioscience), or anti–β-actin mAb (AC-15; Sigma-Aldrich), the membranes were incubated with HRP-conjugated secondary Abs. After washing with PBS–Tween 20 (0.05%), bound HRP-conjugated Abs were detected using Western Lightning Plus-ECL reagents (PerkinElmer Life and Analytical Sciences).

To analyze Ig SHM induced in response to NP immunization, spleen B cells were isolated from C57BL/6 mice that were immunized with NP16-CGG and given untreated water or HDI water. Rearranged V186.2DJH-Cγ1 cDNA encoding the anti-NP IgH chain was amplified using a V186.2 leader–specific forward primer together with a reverse Cγ1-specific primer (13) and Phusion high-fidelity DNA polymerase (New England BioLabs). PCR conditions were 98°C for 10 s, 60°C for 45 s, and 72°C for 1 min for 30 cycles. To analyze spontaneous SHM and deletion in MRL/Faslpr/lpr mice, CD19+PNAhi GC B cells were isolated from Peyer’s patches and used for extraction of genomic DNA. The intronic JH4-iEμ DNA region (downstream of rearranged VJ558DJH4), which is targeted by SHM but not subjected to any positive- or negative-selection pressure, was amplified by nested PCR using Phusion DNA polymerase and two VJ558 framework region 3′-specific forward primers and two reverse primers specific for sequences downstream of JH4, which yielded DNA ∼960 bp if a JH4 rearrangement occurred (49). Amplification conditions for both the first- and second-round PCRs were 30 cycles of 98°C for 10 s, 60°C for 45 s, and 72°C for 1 min. PCR products were cloned into the pCR-Blunt II-TOPO vector (Invitrogen) and sequenced. Sequences were compared with the germline V186.2 or intronic JH4-iEμ DNA region sequences using MacVector software (MacVector) for analysis of point mutations or deletions. For the intronic JH4-iEμ DNA region, only a 700-bp region from rearrangements involving JH4-iEμ was analyzed.

For quantification of mRNA, pri-miRNA, germline IH-CH, and postrecombination Iμ-CH and mature VHDJH-CH transcripts, RNA was extracted from 0.2–5 × 106 cells using either TRIzol reagent (Invitrogen) or an RNeasy Plus Mini Kit (QIAGEN). Residual DNA was removed from the extracted RNA with gDNA eliminator columns (QIAGEN). cDNA was synthesized from total RNA with the SuperScript III First-Strand Synthesis System (Invitrogen) using oligo-dT primer. Transcript expression was measured by quantitative RT-PCR (qRT-PCR) with the appropriate primers (Supplemental Table I) using a MyiQ Real-Time PCR Detection System to measure SYBR Green (IQ SYBR Green Supermix; both from Bio-Rad) incorporation with the following protocol: 95°C for 15 s, 40 cycles of 94°C for 10 s, 60°C for 30 s, and 72°C for 30 s. Data acquisition was performed during the 72°C extension step. Melting-curve analysis was performed from 72 to 95°C. For quantification of mature miRNA transcripts, RNA was extracted from 0.2–5 × 106 cells using an miRNeasy Mini Kit and then reverse transcribed with a miScript II RT Kit (both from QIAGEN) using the miScript HiSpec buffer. A Bio-Rad MyiQ Real-Time PCR Detection System was used to measure SYBR Green (miScript SYBR Green PCR Kit; QIAGEN) incorporation, according to the manufacturer’s instructions. Mature miRNA forward primers (Supplemental Table I) were used at 250 nM in conjunction with the QIAGEN miScript Universal Primer and normalized to expression of small nuclear/nucleolar RNAs Rnu6/RNU61/2, Snord61/SNORD61, Snord68/SNORD68, and Snord70/SNORD70. The ΔΔCt method was used for data analysis of qRT-PCR experiments.

Chromatin immunoprecipitation (ChIP) assays were performed as previously described (15, 48, 50). B cells (1 × 107) were treated with formaldehyde (1% v/v) for 10 min at 25°C to cross-link chromatin, washed once in cold PBS with protease inhibitors (Roche), and resuspended in lysis buffer (20 mM Tris-HCl, 200 mM NaCl, 2 mM EDTA, 0.1% w/v SDS, and protease inhibitors [pH 8]). Chromatin was sonicated to yield DNA fragments (∼200–1000 bp in length), precleared with protein A agarose beads (Pierce), and incubated with anti–acetyl histone H3 mAb (H3K9ac/K14ac; 17-615; Millipore) at 4°C overnight. Immune complexes were precipitated by Protein A agarose beads, washed, and eluted (50 mM Tris-HCl, 0.5% SDS, 200 mM NaCl, 100 μg/ml proteinase K [pH 8]), followed by incubation at 65°C for 4 h. DNA was purified using a QIAquick PCR purification kit (QIAGEN). The miRNA host gene promoter region DNA was amplified from immunoprecipitated chromatin by quantitative PCR (qPCR) using appropriate primers (Supplemental Table I). Data were normalized to input chromatin DNA and depicted as relative abundance of each amplicon.

The partial 3′UTRs of Aicda mRNA (nt 691–1168 of NM_009645.2, National Center for Biotechnology Information) and Prdm1 mRNA (nt 2652–5101 of NM_007548.3, National Center for Biotechnology Information) were PCR amplified from spleen B cell cDNA and cloned into the pMIR-REPORT miRNA Expression Reporter Vector System (Invitrogen), which allows for analysis of 3′UTR-mediated regulation of firefly luciferase activity. The mutant (mut) Aicda 3′UTR containing point mutations (Supplemental Fig. 2E) was generated by PCR-based mutagenesis of the Aicda 3′UTR pMIR-REPORT vector using Phusion DNA polymerase (New England BioLabs.). Point mutations were introduced into the Prdm1 3′UTR, as described above, together with an additional deletion (nt 3680–5101 were deleted by PCR) to generate mut Prdm1 3′UTR. The sequence of constructs was confirmed by two independent sequencing reactions. Reporter constructs were cotransfected with the pRL-TK vector (Promega), which drives constitutive expression of Renilla reniformis luciferase, into mouse CH12F3 B cells by electroporation (250V and 900 Ω) with a Gene Pulser II (Bio-Rad). Transfected CH12F3 B cells were then cultured in FBS-RPMI for 1.5 h to allow for reporter gene expression. The ability of VPA to repress reporter activity was determined by firefly luciferase activity and normalized to Renilla luciferase activity, according to the manufacturer’s instructions, using the Dual-Luciferase Reporter Assay System (Promega).

Genomic DNA was treated with sodium bisulfite using the EpiTect Bisulfite Kit (QIAGEN), according to the manufacturer’s instructions. Bisulfite-treated DNA was amplified by PCR using GoTaq Hot Start Polymerase (Promega). The primers for bisulfite-sequencing PCR (Supplemental Table I) were designed using MethPrimer (http://www.urogene.org/methprimer/index1.html). PCR products were purified with a QIAquick PCR purification kit (QIAGEN) and sequenced before or after being cloned into the pCR-Blunt II-TOPO vector.

MRL/Faslpr/lpr mice (The Jackson Laboratory) were housed in the University of California, Irvine and the UT Health Science Center, San Antonio vivaria and provided with autoclaved food and deionized water. MRL/Faslpr/lpr mice were started on HDI water ad libitum at 6 or 17 wk of age or were on untreated water throughout their life and sacrificed when moribund. Anti-nuclear Ab (ANA) and anti-dsDNA Ab titers were determined in sera. For ANA assays, sera were serially diluted in PBS (from 1:40 to 1:160), incubated on ANA substrate slides (HEp-2 cell–coated slides; MBL-BION), and detected with a 1:1 mixture of FITC–anti-IgG1 and FITC–anti-IgG2a mAbs (R19-15; BD Biosciences). Images were acquired with a 40× objective on an Olympus CKX41 fluorescence microscope. Anti-dsDNA IgG and IgG2a Ab titers were measured in sera of MRL/Faslpr/lpr mice by ELISA, as previously described (14). Titers were expressed in RU, defined as the dilution factor needed to reach 50% of binding saturation, calculated using GraphPad Prism software (GraphPad). Skin lesions were scored on a scale of 0 to 3, with 0 = none, 1 = mild (snout and ears), 2 = moderate (<2 cm snout, ears, and intrascapular), and 3 = severe (>2 cm snout, ears, and intrascapular). To assess kidney pathology, kidneys from MRL/Faslpr/lpr mice were either frozen in Tissue-Tek O.C.T. compound (Sakura Finetek USA) on dry ice for immunofluorescence or fixed in paraformaldehyde (4%) and embedded in paraffin for H&E staining. For immunofluorescence, 4-μm sections were prepared by cryostat, loaded onto positively charged slides, fixed in cold acetone, and stained with a mixture of FITC-labeled rat mAb to mouse IgG1 or mouse IgG2a. Cover slips were mounted using ProLong Gold Antifade Reagent with DAPI before examination with an Olympus CKX41 fluorescence microscope. For H&E staining, kidneys were fixed overnight in paraformaldehyde (4%), serially passed into ethanol (30%) for 1 h, ethanol (50%) for 1 h, and ethanol (70%) overnight, and embedded in paraffin; 4-μm sections were cut for H&E staining.

All statistical analyses were performed using Excel (Microsoft) or GraphPad Prism software. Differences in Ig titers, CSR, and RNA transcript expression were analyzed with a Student paired (in vitro) or unpaired (in vivo) t test, assuming two-tailed distributions. Differences in the frequency and spectrum of somatic point mutations were analyzed with χ2 tests. Differences in lifespan between mice that were administered untreated water or HDI water were compared by Kaplan–Meier curves and calculated using the Mantel–Cox log-rank test.

To address the effect of HDIs on a T-dependent response, we injected C57BL/6 mice with NP16-CGG, which preferentially induces NP-binding IgG1, 1 d after starting them on the HDI water; these mice drank HDI water at a comparable or higher rate than did mice drinking untreated water. Mice drinking HDI water showed a reduced IgG1 (including high-affinity NP3-binding IgG1), but not IgM, response to NP, even after a second injection of NP16-CGG (Fig. 1A, 1B); reduced class-switched NP-binding IgG1 titers occurred in the context of reduced total IgG1, IgG3, and IgG2b (IgG2b data not shown) but not IgM (Fig. 1C). They were associated with reduced proportions of GC IgG1+, but not IgM+, B cells and a reduced frequency of somatic point mutations (by >65%) in V186.2DJH-Cγ1 transcripts, with no significant alteration in spectrum of the residual mutations (Fig. 1D, 1E, Supplemental Fig. 1A), suggesting that this HDI reduced AID expression to impair the class-switched and hypermutated Ab response. In these mice, HDI had no significant effect on T (CD3+) or B (B220+) cell number (Fig. 1F). A “direct” HDI effect on B cells was indicated by the reduced T-independent IgG3 response in HDI-treated mice injected with T-independent NP-LPS. These mice showed reduced titers of (high-affinity) NP3-binding IgG3, as well as fewer total IgG3+ B cells and NP3-binding IgG3 Ab-forming cells (Fig. 1G, 1H). Thus, HDIs can dampen class-switched–specific T-dependent and T-independent Ab responses.

FIGURE 1.

HDIs reduce CSR and SHM in Ab responses to NP-CGG and NP-LPS. Eight-week-old C57BL/6 mice were started on HDI water 1 d before injection with NP16-CGG or NP-LPS. (A) Titers of high-affinity NP3-binding IgM or IgG1 (RU) in serum 10 d after NP16-CGG injection. Each symbol represents an individual mouse (n = 5). (B) NP3-binding IgG1 titers (RU) in serum 28 d after initial NP16-CGG injection (7 d after booster NP16-CGG injection). Each symbol represents an individual mouse (n = 3). (C) Titers of total IgM, IgG1, or IgG3 in serum 10 d after NP16-CGG injection (n ≥ 5 mice). (D) Surface IgM and IgG1 expression in spleen B220+PNAhi GC B cells 10 d after NP16-CGG injection. Data are representative of three independent experiments. (E) Somatic point mutations in the V186.2 region of V186.2DJH-Cγ1 transcripts amplified from spleen B cells 10 d after NP16-CGG injection. Sequence data were pooled from three mice in each group. Pie charts depict the proportions of sequences that carry 1, 2, 3, and so on point mutations over the 294-bp V186.2 region of V186.2DJH-Cγ1 transcripts. In the center is the number of independent sequences analyzed; listed below the pie charts is the overall mutation frequency (changes/base). (F) Surface B220 and CD3 expression in spleen cells 10 d after NP16-CGG injection. Data are representative of three independent experiments. (G) NP3-binding IgG3 titers (RU) in serum 28 d after initial NP-LPS injection (7 d after booster NP-LPS injection). Each symbol represents an individual mouse (n = 4). (H) ELISPOT analysis of NP3-binding IgG3 Ab-forming cells (AFCs) in spleens 28 d after initial NP-LPS injection (7 d after booster NP-LPS injection). Data are from three independent experiments. Scale bars, 1 mm. Numbers indicate NP3-binding IgG3 AFCs/1 × 106 spleen cells (n = 3 mice). The p values were determined using an unpaired t test.

FIGURE 1.

HDIs reduce CSR and SHM in Ab responses to NP-CGG and NP-LPS. Eight-week-old C57BL/6 mice were started on HDI water 1 d before injection with NP16-CGG or NP-LPS. (A) Titers of high-affinity NP3-binding IgM or IgG1 (RU) in serum 10 d after NP16-CGG injection. Each symbol represents an individual mouse (n = 5). (B) NP3-binding IgG1 titers (RU) in serum 28 d after initial NP16-CGG injection (7 d after booster NP16-CGG injection). Each symbol represents an individual mouse (n = 3). (C) Titers of total IgM, IgG1, or IgG3 in serum 10 d after NP16-CGG injection (n ≥ 5 mice). (D) Surface IgM and IgG1 expression in spleen B220+PNAhi GC B cells 10 d after NP16-CGG injection. Data are representative of three independent experiments. (E) Somatic point mutations in the V186.2 region of V186.2DJH-Cγ1 transcripts amplified from spleen B cells 10 d after NP16-CGG injection. Sequence data were pooled from three mice in each group. Pie charts depict the proportions of sequences that carry 1, 2, 3, and so on point mutations over the 294-bp V186.2 region of V186.2DJH-Cγ1 transcripts. In the center is the number of independent sequences analyzed; listed below the pie charts is the overall mutation frequency (changes/base). (F) Surface B220 and CD3 expression in spleen cells 10 d after NP16-CGG injection. Data are representative of three independent experiments. (G) NP3-binding IgG3 titers (RU) in serum 28 d after initial NP-LPS injection (7 d after booster NP-LPS injection). Each symbol represents an individual mouse (n = 4). (H) ELISPOT analysis of NP3-binding IgG3 Ab-forming cells (AFCs) in spleens 28 d after initial NP-LPS injection (7 d after booster NP-LPS injection). Data are from three independent experiments. Scale bars, 1 mm. Numbers indicate NP3-binding IgG3 AFCs/1 × 106 spleen cells (n = 3 mice). The p values were determined using an unpaired t test.

Close modal

To further define the impact of HDIs on CSR, we used appropriate stimuli to induce B cells to switch to IgG1, IgG3, IgA, or IgE in the presence of VPA, butyrate (0–1000 μM), or TSA (0–20 nM). These HDIs reduced, in a dose-dependent fashion, CSR to IgG1, IgG3, IgA, and IgE (Figs. 2A, 2B, 3A–C, Supplemental Fig. 1B) without affecting B cell division (Fig. 2C, 2D), viability, or apoptosis in vivo or in vitro (Fig. 4A, Supplemental Fig. 1C, 1D). Expression of the antiapoptotic genes Bcl2, Mcl1, and Bcl2l1 (Bcl2l1 encodes Bcl-xL), which enhance B cell and plasma cell survival, was unaltered or increased by HDIs in vivo and in vitro (Supplemental Fig. 1F, 1H). The reduction in IgG1+ and IgG3+ B cells reflected a lower proportion of class-switched cells/round of cell division (Fig. 2C, 2D, Supplemental Fig. 2A) and was associated with decreased titers of IgG1, IgG3, IgA, and IgE in culture fluids (Fig. 3D, 3E). HDI inhibition of CSR was further confirmed by decreased mature VHDJH-Cγ1, VHDJH-Cγ3, VHDJH-Cα, and VHDJH-Cε transcripts and postrecombination Iμ-Cγ1, Iμ-Cγ1, Iμ-Cγ3, Iμ-Cα, and Iμ-Cε transcripts in the presence of normal levels of the respective germline IH-CH transcripts, which are necessary for initiation of CSR (Supplemental Fig. 2B–D). Thus, HDIs significantly reduce CSR, without altering B cell viability or proliferation.

FIGURE 2.

Dose-dependent inhibition of CSR by HDIs in B cells. (A) Surface expression of B220 and IgG1 or IgG3 on B cells stimulated with LPS + IL-4 or CD154 + IL-4 (for CSR to IgG1) or LPS (for CSR to IgG3) in the presence of nil or increasing doses of VPA (concentrations comparable to or lower than serum concentrations of VPA-treated mice) for 4 d. (B) Surface expression of B220 and IgG1 or IgA or intracellular expression of B220 and IgE in B cells stimulated with CD154 + IL-4 (for CSR to IgG1 and IgE) or LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran (for CSR to IgA) in the presence of nil or increasing doses of butyrate for 4 d. Proliferation of lymph node B220+ B cells labeled with CFSE and stimulated for 4 d with LPS + IL-4 in the presence of nil, VPA (500 μM) (C), or butyrate (500 μM) (D). Progressive left shift of fluorescence intensity indicates B220+ B cell division (left panels). Cell divisions are plotted by vertical lines versus IgG1 surface density, among B220+ cells (middle panels). The percentages of IgG1+B220+ B cells among total B220+ B cells that had completed the same number of divisions when cultured for 4 d in the presence of nil, VPA, or butyrate (right panels). Data are representative of three independent experiments.

FIGURE 2.

Dose-dependent inhibition of CSR by HDIs in B cells. (A) Surface expression of B220 and IgG1 or IgG3 on B cells stimulated with LPS + IL-4 or CD154 + IL-4 (for CSR to IgG1) or LPS (for CSR to IgG3) in the presence of nil or increasing doses of VPA (concentrations comparable to or lower than serum concentrations of VPA-treated mice) for 4 d. (B) Surface expression of B220 and IgG1 or IgA or intracellular expression of B220 and IgE in B cells stimulated with CD154 + IL-4 (for CSR to IgG1 and IgE) or LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran (for CSR to IgA) in the presence of nil or increasing doses of butyrate for 4 d. Proliferation of lymph node B220+ B cells labeled with CFSE and stimulated for 4 d with LPS + IL-4 in the presence of nil, VPA (500 μM) (C), or butyrate (500 μM) (D). Progressive left shift of fluorescence intensity indicates B220+ B cell division (left panels). Cell divisions are plotted by vertical lines versus IgG1 surface density, among B220+ cells (middle panels). The percentages of IgG1+B220+ B cells among total B220+ B cells that had completed the same number of divisions when cultured for 4 d in the presence of nil, VPA, or butyrate (right panels). Data are representative of three independent experiments.

Close modal
FIGURE 3.

HDIs inhibit CSR, as well as IgG, IgA, and IgE production, in a dose-dependent fashion, but they do not affect GC formation. (A) Surface expression of B220 and IgA in B cells stimulated with CD154 or LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran in the presence of nil or increasing doses of VPA for 4 d. (B) Intracellular expression of IgE in B cells stimulated with CD154 + IL-4 in the presence of nil or increasing doses of VPA for 4 d. (C) Intracellular expression of IgM and IgG1 in B cells stimulated with LPS + IL-4 for 4 d in the presence of nil or VPA. (D) IgG1, IgG3, IgA, or IgE in culture fluids of B cells stimulated with LPS + IL-4, LPS alone, LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran, or CD154 + IL-4, respectively, for 7 d in the presence of nil or increasing doses of VPA. (E) IgG1, IgA, and IgE in culture fluids of B cells stimulated with CD154 + IL-4 or LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran for 7 d in the presence of nil or butyrate. Data are from three independent experiments (mean and SEM). (F) Proportions of IgG1+ plasmablasts (B220+CD138+), as measured by surface expression of B220, CD138, and IgG1 in B cells stimulated with LPS + IL-4 for 7 d in the presence of nil or VPA. (G) GC structure, as visualized by fluorescent microscopy (B220, red; PNA-binding lectin, green). Spleen sections prepared from mice that were on HDI water or untreated water and injected with NP16-CGG for 10 d (as in Fig. 1). GC B cells were identified by staining with PE–anti-B220 mAb and FITC-PNA. Data are representative of three independent experiments. Scale bars, 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001 unpaired t test.

FIGURE 3.

HDIs inhibit CSR, as well as IgG, IgA, and IgE production, in a dose-dependent fashion, but they do not affect GC formation. (A) Surface expression of B220 and IgA in B cells stimulated with CD154 or LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran in the presence of nil or increasing doses of VPA for 4 d. (B) Intracellular expression of IgE in B cells stimulated with CD154 + IL-4 in the presence of nil or increasing doses of VPA for 4 d. (C) Intracellular expression of IgM and IgG1 in B cells stimulated with LPS + IL-4 for 4 d in the presence of nil or VPA. (D) IgG1, IgG3, IgA, or IgE in culture fluids of B cells stimulated with LPS + IL-4, LPS alone, LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran, or CD154 + IL-4, respectively, for 7 d in the presence of nil or increasing doses of VPA. (E) IgG1, IgA, and IgE in culture fluids of B cells stimulated with CD154 + IL-4 or LPS + TGF-β + IL-4 + IL-5 + anti-IgD dextran for 7 d in the presence of nil or butyrate. Data are from three independent experiments (mean and SEM). (F) Proportions of IgG1+ plasmablasts (B220+CD138+), as measured by surface expression of B220, CD138, and IgG1 in B cells stimulated with LPS + IL-4 for 7 d in the presence of nil or VPA. (G) GC structure, as visualized by fluorescent microscopy (B220, red; PNA-binding lectin, green). Spleen sections prepared from mice that were on HDI water or untreated water and injected with NP16-CGG for 10 d (as in Fig. 1). GC B cells were identified by staining with PE–anti-B220 mAb and FITC-PNA. Data are representative of three independent experiments. Scale bars, 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001 unpaired t test.

Close modal
FIGURE 4.

HDIs inhibit plasma cell differentiation. (A) Proportions of B220+PNAhi GC B cells, proliferating B cells (BrdU-stained B220+ B cells), viable (7-AAD) B220+ B cells, and CD4+ and CD8+ T cells in spleen cells from mice that were on HDI water or untreated water and injected with NP16-CGG 10 d before analysis. (B) HDI does not alter B cell cycle. Mouse IgD+ B cells were stimulated for 48 h with LPS or LPS + IL-4 in the presence of nil or VPA; during the last 30 min of culture, the cells were pulse-labeled with 10 μM of BrdU. The cells were then surface stained for B220 before intracellular staining with anti-BrdU mAb and 7-AAD. B220+ cells are displayed, with gates indicating the percentage of cells in G0/G1, S, and G2/M phase. (C) Proportions of B220loCD138+ (plasma) cells in spleen cells from C57BL/6 mice that were on HDI water or untreated water were analyzed 10 d after NP16-CGG injection. (D) Dose-dependent inhibition by VPA of plasma cell (B220loCD138+) differentiation (upper panels) in B cells stimulated for 4 d with LPS + IL-4, without alteration of plasma cell viability, as analyzed by 7-AAD staining (lower panels, proportions of 7-AAD viable cells among B220loCD138+ cells are indicated). (E) IgG1-producing plasma cells (IgG1+CD138+ or IgG1+Blimp-1+) are reduced in cultures of IgD+ B cells stimulated for 7 d with LPS + IL-4 in the presence of VPA (500 μM), as shown by confocal fluorescence microscopy. Cells were permeabilized and stained with DAPI (blue) to visualize nuclei and fluorescent mAbs to visualize IgG1 (green) and CD138 (red, upper set of panels) or Blimp-1 (red, lower set of panels). Arrows indicate IgG1-producing cells (yellow; CD138+/Blimp-1+IgG1+). Data are representative of three independent experiments. Scale bars, 10 μm.

FIGURE 4.

HDIs inhibit plasma cell differentiation. (A) Proportions of B220+PNAhi GC B cells, proliferating B cells (BrdU-stained B220+ B cells), viable (7-AAD) B220+ B cells, and CD4+ and CD8+ T cells in spleen cells from mice that were on HDI water or untreated water and injected with NP16-CGG 10 d before analysis. (B) HDI does not alter B cell cycle. Mouse IgD+ B cells were stimulated for 48 h with LPS or LPS + IL-4 in the presence of nil or VPA; during the last 30 min of culture, the cells were pulse-labeled with 10 μM of BrdU. The cells were then surface stained for B220 before intracellular staining with anti-BrdU mAb and 7-AAD. B220+ cells are displayed, with gates indicating the percentage of cells in G0/G1, S, and G2/M phase. (C) Proportions of B220loCD138+ (plasma) cells in spleen cells from C57BL/6 mice that were on HDI water or untreated water were analyzed 10 d after NP16-CGG injection. (D) Dose-dependent inhibition by VPA of plasma cell (B220loCD138+) differentiation (upper panels) in B cells stimulated for 4 d with LPS + IL-4, without alteration of plasma cell viability, as analyzed by 7-AAD staining (lower panels, proportions of 7-AAD viable cells among B220loCD138+ cells are indicated). (E) IgG1-producing plasma cells (IgG1+CD138+ or IgG1+Blimp-1+) are reduced in cultures of IgD+ B cells stimulated for 7 d with LPS + IL-4 in the presence of VPA (500 μM), as shown by confocal fluorescence microscopy. Cells were permeabilized and stained with DAPI (blue) to visualize nuclei and fluorescent mAbs to visualize IgG1 (green) and CD138 (red, upper set of panels) or Blimp-1 (red, lower set of panels). Arrows indicate IgG1-producing cells (yellow; CD138+/Blimp-1+IgG1+). Data are representative of three independent experiments. Scale bars, 10 μm.

Close modal

HDI-mediated impairment of Ab responses was not due to alteration of GC development, because GC structure, GC B cell proportion, and B cell viability and proliferation were unaltered in NP-CGG–injected mice treated with VPA (Figs. 3G, 4A), nor did it stem from alteration of the cell cycle, as shown by the normal proportion of B cells in G0/G1, S, or G2/M upon stimulation in vitro (Fig. 4B). Rather, it reflected an HDI-mediated inhibition of B cell differentiation into plasma cells in vivo and in vitro (Fig. 4C–E). This was not associated with decreased plasma cell survival, as shown by normal plasma cell viability and apoptosis, as well as elevated Bcl2, Mcl1, and Bcl2l1 expression (Fig. 4D, Supplemental Fig. 1E, 1G, 1I) and normal transcripts of Il6 (data not shown), which enhances Blimp-1 expression (51). Thus, HDIs inhibit plasma cell differentiation without altering plasma cell survival.

The HDI-impaired Ab response was associated with reduced CSR and SHM, which are initiated by AID, and reduced plasma cell differentiation, which is orchestrated by Blimp-1. Expression of Aicda, Prdm1, and Xbp1 [Xbp1 is under control of Blimp-1 and its gene product promotes Ig secretion in plasma cells (16)] was significantly reduced by HDIs in vivo. Expression of Ung, which encodes for Ung that plays a role downstream of AID in CSR and SHM (1), and Bcl6, which encode Bcl-6, a master regulator of the GC reaction and a Prdm1 repressor (52, 53), were unchanged (Fig. 5A). Consistent with these in vivo findings, the expression of Aicda, Prdm1, and Xbp1 was silenced in a dose-dependent fashion by HDIs in stimulated B cells in vitro (Fig. 5B–D). This contrasted with the unchanged expression of Irf4 (encoding Irf4, a transcription factor that regulates CSR, SHM, and plasma cell differentiation) (54), Bcl6, Ung, HoxC4 (encoding the AID-inducing HoxC4 transcription factor) (1214), Rev1 (encoding the CSR scaffold protein Rev1) (48), and Bach2 and Pax5 (encoding Bach2 and Pax5, both repressors of Prdm1) (55, 56) (Fig. 5C, data not shown). The downregulation of Aicda and Prdm1 transcripts greatly affected the expression of AID and Blimp-1 proteins (Fig. 5E). Thus, the inhibition of CSR, SHM, and plasma cell differentiation by HDIs reflects the HDI-mediated downregulation of AID and Blimp-1.

FIGURE 5.

HDIs reduce expression of AID (Aicda), Blimp-1 (Prdm1), and Xbp-1 (Xbp1) in a dose-dependent fashion in B cells. (A) Aicda, Ung, Prdm1, Xbp1, and Bcl6 transcripts in spleen B cells from C57BL/6 mice that were on HDI water or untreated water and injected with NP16-CGG 10 d before analysis, as in Fig. 1, were measured by qRT-PCR and normalized to Gapdh expression. Values for the B cells from HDI (VPA)-treated mice are depicted as relative to the expression of each transcript in the B cells from untreated (nil) mice, set as 1. Data are mean and SEM from at least three pairs of mice. The p values were determined using an unpaired t test. (B) Aicda transcripts in purified B cells treated with nil (0 μM of VPA) or VPA (250 or 1000 μM) and stimulated for 60 h with LPS or CD154 + IL-4, or LPS or CD154 + TGF-β + IL-4 + IL-5 + anti-IgD dextran were measured by qRT-PCR and normalized to Cd79b expression. (C) Prdm1, Xbp1, Irf4, Bcl-6, Ung, Rev1, Bach2, and Pax5 transcripts in purified B cells treated with nil or increasing doses of VPA and stimulated for 60 h with LPS or LPS + IL-4 were measured by qRT-PCR and normalized to Cd79b expression. (D) Aicda and Prdm1 transcripts in B cells treated with nil or butyrate (1000 μM) and stimulated for 60 h with LPS + IL-4 were measured by qRT-PCR and normalized to Cd79b expression. Values in B cells cultured in the presence of HDI are depicted as relative to the expression of each transcript in B cells cultured in the absence of HDI, set as 1. Data are mean and SEM from three independent experiments. (E) AID, Blimp-1, and β-actin proteins in cell lysates from B cells cultured for 60 h with LPS + IL-4 or CD154 + IL-4 in the presence of nil or HDI (1000 μM of VPA or butyrate) were detected by immunoblotting. Data are representative of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 unpaired t test.

FIGURE 5.

HDIs reduce expression of AID (Aicda), Blimp-1 (Prdm1), and Xbp-1 (Xbp1) in a dose-dependent fashion in B cells. (A) Aicda, Ung, Prdm1, Xbp1, and Bcl6 transcripts in spleen B cells from C57BL/6 mice that were on HDI water or untreated water and injected with NP16-CGG 10 d before analysis, as in Fig. 1, were measured by qRT-PCR and normalized to Gapdh expression. Values for the B cells from HDI (VPA)-treated mice are depicted as relative to the expression of each transcript in the B cells from untreated (nil) mice, set as 1. Data are mean and SEM from at least three pairs of mice. The p values were determined using an unpaired t test. (B) Aicda transcripts in purified B cells treated with nil (0 μM of VPA) or VPA (250 or 1000 μM) and stimulated for 60 h with LPS or CD154 + IL-4, or LPS or CD154 + TGF-β + IL-4 + IL-5 + anti-IgD dextran were measured by qRT-PCR and normalized to Cd79b expression. (C) Prdm1, Xbp1, Irf4, Bcl-6, Ung, Rev1, Bach2, and Pax5 transcripts in purified B cells treated with nil or increasing doses of VPA and stimulated for 60 h with LPS or LPS + IL-4 were measured by qRT-PCR and normalized to Cd79b expression. (D) Aicda and Prdm1 transcripts in B cells treated with nil or butyrate (1000 μM) and stimulated for 60 h with LPS + IL-4 were measured by qRT-PCR and normalized to Cd79b expression. Values in B cells cultured in the presence of HDI are depicted as relative to the expression of each transcript in B cells cultured in the absence of HDI, set as 1. Data are mean and SEM from three independent experiments. (E) AID, Blimp-1, and β-actin proteins in cell lysates from B cells cultured for 60 h with LPS + IL-4 or CD154 + IL-4 in the presence of nil or HDI (1000 μM of VPA or butyrate) were detected by immunoblotting. Data are representative of three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001 unpaired t test.

Close modal

Enhancement of histone acetylation, a function of HDIs, which generally upregulate gene expression, is at odds with the decreased expression of AID/Aicda and Blimp-1/Prdm1 by HDIs in vivo and in vitro (Fig. 5). In fact, in B cells induced to undergo CSR, HDIs did not alter histone H3 acetylation in the Aicda promoter, nor did they alter DNA methylation [HDACs were suggested to interact with DNA methyltransferases (57)] (Fig. 6A–C), raising the possibility that HDIs upregulated the expression of gene(s), which, in turn, negatively regulated Aicda and Prdm1. HDIs can modulate expression of miRNAs (36), which silence target mRNAs by inducing their degradation and/or reducing their translation. In this context, Aicda can be silenced by miR-155, miR-181b, and miR-361 (2, 3, 18, 2730); Prdm1 can be targeted by miR-23b (our prediction, using TargetScan.org, miRNA.org, and miRbase.org) and was suggested to be targeted by miR-30a and miR-125b (3, 18, 3133) (Supplemental Fig. 2E). We found that miR-155, miR-181b, miR-361, miR-23b, miR-30a, and miR-125b were upregulated by VPA in B cells in vivo; in purified B cells induced to undergo CSR and plasma cell differentiation in vitro, irrelevant miRNAs miR-19a/b, miR-20a, and miR-25, which are not known to regulate Aicda, Prdm1, or Xbp1, were unchanged in B cells in vivo and in vitro (Fig. 7A, 7B). Primary miRNA transcripts pri–miR-155 and pri–miR-181b, which are processed by Drosha and Dicer to give rise to mature miRNAs, also were upregulated, suggesting that HDIs upregulate miRNA host gene transcription (Fig. 6D). Accordingly, miRNA upregulation in stimulated B cells was accompanied by increased overall histone H3 acetylation of the host genes encoding these miRNAs (Fig. 7C). Thus, HDIs upregulate miRNAs that target Aicda and Prdm1 mRNA 3′ UTRs and, therefore, can silence these mRNAs.

FIGURE 6.

HDIs do not alter DNA methylation and histone acetylation in the Aicda promoter. (A and B) CpG DNA methylation of the Aicda promoter was analyzed by bisulfite sequencing of genomic DNA from B cells stimulated for 4 d with LPS + IL-4 in the presence of increasing doses of VPA. (A) DNA sequencing of PCR products of bisulfite-treated genomic DNA. The sequence signal from dCs in CpG motifs is outlined. Because unmethylated dC nucleotides can be converted to dU (read as dT in DNA sequence), whereas methylated dC cannot, the ratio of the dC (blue)/dT (red) signal indicates the level of methylated dC at any given position. (B) Methylation pattern at each of the four dCs within CpG motifs from individually cloned sequences (each row is a unique sequence, and each dC is represented by a column of circles) is shown as an array of circles. ●, methylated dCs; ○, unmethylated dCs. (C) Abundance of acetylated histone H3 (H3K9ac/K14ac) in the Aicda promoter in B cells stimulated with LPS + IL-4 for 60 h in the presence of nil or VPA (1000 μM) was measured by ChIP and qPCR. (D) Primary (pri-) miRNA transcripts of miR-155 and miR-181b in B cells cultured for 60 h with LPS or LPS + IL-4 in the presence of nil or increasing doses of VPA were measured by qRT-PCR and normalized to Cd79b expression. Values for B cells cultured in medium containing VPA are depicted as relative to the values in B cells cultured in the absence of HDI, set as 1. Data are mean and SEM from three independent experiments. *p < 0.05, **p < 0.01 unpaired t test.

FIGURE 6.

HDIs do not alter DNA methylation and histone acetylation in the Aicda promoter. (A and B) CpG DNA methylation of the Aicda promoter was analyzed by bisulfite sequencing of genomic DNA from B cells stimulated for 4 d with LPS + IL-4 in the presence of increasing doses of VPA. (A) DNA sequencing of PCR products of bisulfite-treated genomic DNA. The sequence signal from dCs in CpG motifs is outlined. Because unmethylated dC nucleotides can be converted to dU (read as dT in DNA sequence), whereas methylated dC cannot, the ratio of the dC (blue)/dT (red) signal indicates the level of methylated dC at any given position. (B) Methylation pattern at each of the four dCs within CpG motifs from individually cloned sequences (each row is a unique sequence, and each dC is represented by a column of circles) is shown as an array of circles. ●, methylated dCs; ○, unmethylated dCs. (C) Abundance of acetylated histone H3 (H3K9ac/K14ac) in the Aicda promoter in B cells stimulated with LPS + IL-4 for 60 h in the presence of nil or VPA (1000 μM) was measured by ChIP and qPCR. (D) Primary (pri-) miRNA transcripts of miR-155 and miR-181b in B cells cultured for 60 h with LPS or LPS + IL-4 in the presence of nil or increasing doses of VPA were measured by qRT-PCR and normalized to Cd79b expression. Values for B cells cultured in medium containing VPA are depicted as relative to the values in B cells cultured in the absence of HDI, set as 1. Data are mean and SEM from three independent experiments. *p < 0.05, **p < 0.01 unpaired t test.

Close modal
FIGURE 7.

HDIs hyperacetylate miRNA host genes to upregulate miRNAs that silence Aicda and Prdm1 mRNAs. (A) Upregulation of miRNAs that modulate AID and Blimp-1 in “total” (spleen CD19+CD138) B cells, naive B cells, and plasma cells from mice that were on HDI water or untreated water and injected with NP16-CGG (as in Fig. 1) was measured by qRT-PCR. (B) Expression of miRNAs that modulate AID and Blimp-1 in freshly isolated naive B cells and in B cells stimulated with LPS + IL-4 for 60 h (left panel). Dose-dependent upregulation of miRNAs that modulate AID and Blimp-1 in B cells cultured with LPS + IL-4 for 60 h in the presence of nil or VPA (250 or 1000 μM) (right panel). miRNA expression was normalized to expression of small nuclear/nucleolar RNAs Rnu6, Snord61, Snord68, and Snord70. miRNA expression in B cells isolated from mice that were on HDI water or B cells cultured with HDI are depicted as relative to the expression of each miRNA in B cells isolated from mice that were on untreated water, or B cells cultured in the absence of HDI, respectively, set as 1. Data are mean and SEM from at least three mice or three independent experiments. (C) Relative abundance of acetylated histone H3 (H3K9ac/K14ac) in miRNA host genes (HGs) in purified B cells stimulated with LPS + IL-4 in the presence of nil or VPA (500 μM), as analyzed by ChIP and qPCR. (D) Mature miRNA expression in CH12F3 B cells treated with nil or VPA (250 μM) for 24 h, as measured by qRT-PCR. Values for B cells treated with VPA are depicted as relative to the expression of each miRNA in B cells treated with nil, set as 1. (E) Schematic diagram of the 3′UTRs of Aicda and Prdm1 mRNAs and their mutant (Mut) counterparts that were cloned into the pMIR-REPORT luciferase reporter vector. Open boxes indicate point mutation sequences that are putative miRNA target sites, as detailed in Supplemental Fig. 2E. Mut Prdm1 3′UTR consists of a DNA deletion. (F) Luciferase activity in CH12F3 cells transfected with wild-type or mut Aicda or Prdm1 3′UTRs (cloned into pMIR-REPORT luciferase reporter vector) after a 24-h treatment with nil or VPA (250 μM). Luciferase activity was measured 1.5 h after transfection. Transfection efficiency was controlled for by normalizing to signal from cotransfected R. reniformis luciferase vector. Luciferase activity in B cells treated with VPA is depicted as relative to values in B cells cultured in the absence of VPA, set as 1. Data are mean and SEM from three independent experiments. The p values were determined using an unpaired t test. *p < 0.05, **p < 0.001 unpaired t test.

FIGURE 7.

HDIs hyperacetylate miRNA host genes to upregulate miRNAs that silence Aicda and Prdm1 mRNAs. (A) Upregulation of miRNAs that modulate AID and Blimp-1 in “total” (spleen CD19+CD138) B cells, naive B cells, and plasma cells from mice that were on HDI water or untreated water and injected with NP16-CGG (as in Fig. 1) was measured by qRT-PCR. (B) Expression of miRNAs that modulate AID and Blimp-1 in freshly isolated naive B cells and in B cells stimulated with LPS + IL-4 for 60 h (left panel). Dose-dependent upregulation of miRNAs that modulate AID and Blimp-1 in B cells cultured with LPS + IL-4 for 60 h in the presence of nil or VPA (250 or 1000 μM) (right panel). miRNA expression was normalized to expression of small nuclear/nucleolar RNAs Rnu6, Snord61, Snord68, and Snord70. miRNA expression in B cells isolated from mice that were on HDI water or B cells cultured with HDI are depicted as relative to the expression of each miRNA in B cells isolated from mice that were on untreated water, or B cells cultured in the absence of HDI, respectively, set as 1. Data are mean and SEM from at least three mice or three independent experiments. (C) Relative abundance of acetylated histone H3 (H3K9ac/K14ac) in miRNA host genes (HGs) in purified B cells stimulated with LPS + IL-4 in the presence of nil or VPA (500 μM), as analyzed by ChIP and qPCR. (D) Mature miRNA expression in CH12F3 B cells treated with nil or VPA (250 μM) for 24 h, as measured by qRT-PCR. Values for B cells treated with VPA are depicted as relative to the expression of each miRNA in B cells treated with nil, set as 1. (E) Schematic diagram of the 3′UTRs of Aicda and Prdm1 mRNAs and their mutant (Mut) counterparts that were cloned into the pMIR-REPORT luciferase reporter vector. Open boxes indicate point mutation sequences that are putative miRNA target sites, as detailed in Supplemental Fig. 2E. Mut Prdm1 3′UTR consists of a DNA deletion. (F) Luciferase activity in CH12F3 cells transfected with wild-type or mut Aicda or Prdm1 3′UTRs (cloned into pMIR-REPORT luciferase reporter vector) after a 24-h treatment with nil or VPA (250 μM). Luciferase activity was measured 1.5 h after transfection. Transfection efficiency was controlled for by normalizing to signal from cotransfected R. reniformis luciferase vector. Luciferase activity in B cells treated with VPA is depicted as relative to values in B cells cultured in the absence of VPA, set as 1. Data are mean and SEM from three independent experiments. The p values were determined using an unpaired t test. *p < 0.05, **p < 0.001 unpaired t test.

Close modal

To prove that HDI inhibition of AID and Blimp-1 expression was mediated by upregulation of miRNAs that directly target Aicda and Prdm1 mRNA 3′UTRs, we cloned either wild-type or mut 3′UTRs of Aicda and Prdm1 mRNAs (mut 3′UTRs were constructed by mutation or deletion of the target sites of miR-155 and miR-181b in Aicda mRNA 3′UTR or miR-23b, miR-30a, and miR-125b in Prdm1 mRNA 3′UTR) into pMIR-REPORT luciferase reporter vectors. These were used to transfect mouse CH12F3 B cells that can be induced to undergo CSR at a high rate. Like in primary B cells, VPA upregulated miR-155, miR-181b, miR-361, miR-23b, miR-30a, and miR-125b expression in CH12F3 B cells induced to undergo CSR (Fig. 7D). We then measured the ability of VPA to repress luciferase activity using reporter constructs containing wild-type or mut 3′UTRs of Aicda and Prdm1 mRNAs that were transfected into CH12F3 B cells (Fig. 7E; Supplemental Fig. 2E). The luciferase reporter activity was reduced by VPA in B cells transfected with reporter constructs containing wild-type Aicda or Prdm1 3′UTRs but not those transfected with reporter constructs containing Aicda or Prdm1 mut 3′UTRs (Fig. 7F). In B cells transfected with reporter constructs containing wild-type Aicda or Prdm1 3′UTRs, the degree of inhibition of luciferase activity was significant, despite the relatively low dose of VPA used (250 μM) and the omission of some additional miRNA target sites in the 3′UTR of Aicda mRNA, thereby emphasizing the potency of the HDI-mediated upregulation of miRNAs on B cell gene expression. Thus, VPA silences AID and Blimp-1 expression in B cells through upregulation of selected miRNAs that directly target Aicda and Prdm1 mRNA 3′UTRs.

Next, we determined whether HDIs also inhibit CSR and plasma cell differentiation in human B cells. We stimulated purified human IgD+ B cells with CD154 + IL-21 and IL-4 or TGF-β. Like in mouse B cells, VPA and butyrate effectively inhibited CSR to IgG, IgA, and IgE in human B lymphocytes, as well as plasma cell differentiation in a dose-dependent fashion without altering B cell viability (Fig. 8A–D). VPA increased expression of miR-155, miR-181b, miR-361, miR-23b, miR-30a, and miR-125b, which [as reported or as predicted by us (2, 3, 18, 2733)] target miRNA binding sites in 3′UTR of human and mouse AICDA/Aicda or PRDM1/Prdm1, and decreased expression of AICDA, PRDM1, and XBP1 transcripts (Fig. 8E, 8F). Thus, HDIs (VPA and butyrate) modulate human B cell class-switching and plasma cell differentiation, as they do in mouse B cells.

FIGURE 8.

HDIs inhibit CSR and plasma cell differentiation increases selected miRNAs and decreases target AICDA and PRDM1 mRNAs, as well as XBP1 mRNA, in human B cells. Human peripheral blood IgD+ B cells were stimulated with CD154, human IL-4, and human IL-21 (for CSR to IgG1 and IgE and plasma cell differentiation) or CD154, human IL-21, and TGF-β (for CSR to IgA) in the presence of nil, VPA, or butyrate for 60 h (for transcript or miRNA analysis) or 120 h (for flow cytometry or analysis of Ig titers in supernatants). (A) Proportions of IgG+ B cells, plasma cells (CD27+CD38+), or viable (7-AAD) CD19+ cells. (B) Proportions of IgA+ B cells. (C) IgG and IgA titers in supernatants of B cells stimulated with CD154, human IL-4, and human IL-21 (upper panel) or CD154, human IL-21, and TGF-β (lower panel) and cultured in the presence of VPA or butyrate. Data are from three independent experiments (mean and SEM). *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test. (D) Mature VHDJH-Cα (in cells stimulated by CD154, human IL-21, and TGF-β) and VHDJH-Cγ1 and VHDJH-Cε (in cells stimulated with CD154, human IL-4, and human IL-21) transcripts were analyzed by qRT-PCR and normalized to HPRT1 transcripts. (E) AICDA, PRDM1, and XBP1 transcripts (in cells stimulated with CD154, human IL-4, and human IL-21) were analyzed by qRT-PCR and normalized to HPRT1 transcripts. (F) miRNA expression was analyzed by qRT-PCR and normalized to expression of small nuclear/nucleolar RNAs RNU6-1/2, SNORD61, SNORD68, and SNORD70. Values for B cells cultured in the presence of HDIs are depicted as relative to the expression of each transcript or miRNA in B cells cultured in the absence of HDI, set as 1. Data are mean and SEM from three independent experiments. The p values were determined using an unpaired t test.

FIGURE 8.

HDIs inhibit CSR and plasma cell differentiation increases selected miRNAs and decreases target AICDA and PRDM1 mRNAs, as well as XBP1 mRNA, in human B cells. Human peripheral blood IgD+ B cells were stimulated with CD154, human IL-4, and human IL-21 (for CSR to IgG1 and IgE and plasma cell differentiation) or CD154, human IL-21, and TGF-β (for CSR to IgA) in the presence of nil, VPA, or butyrate for 60 h (for transcript or miRNA analysis) or 120 h (for flow cytometry or analysis of Ig titers in supernatants). (A) Proportions of IgG+ B cells, plasma cells (CD27+CD38+), or viable (7-AAD) CD19+ cells. (B) Proportions of IgA+ B cells. (C) IgG and IgA titers in supernatants of B cells stimulated with CD154, human IL-4, and human IL-21 (upper panel) or CD154, human IL-21, and TGF-β (lower panel) and cultured in the presence of VPA or butyrate. Data are from three independent experiments (mean and SEM). *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test. (D) Mature VHDJH-Cα (in cells stimulated by CD154, human IL-21, and TGF-β) and VHDJH-Cγ1 and VHDJH-Cε (in cells stimulated with CD154, human IL-4, and human IL-21) transcripts were analyzed by qRT-PCR and normalized to HPRT1 transcripts. (E) AICDA, PRDM1, and XBP1 transcripts (in cells stimulated with CD154, human IL-4, and human IL-21) were analyzed by qRT-PCR and normalized to HPRT1 transcripts. (F) miRNA expression was analyzed by qRT-PCR and normalized to expression of small nuclear/nucleolar RNAs RNU6-1/2, SNORD61, SNORD68, and SNORD70. Values for B cells cultured in the presence of HDIs are depicted as relative to the expression of each transcript or miRNA in B cells cultured in the absence of HDI, set as 1. Data are mean and SEM from three independent experiments. The p values were determined using an unpaired t test.

Close modal

Lupus-prone MRL/Faslpr/lpr mice spontaneously upregulate AID, Blimp-1, CSR, and SHM and generate great numbers of plasma cells, which produce large amounts of anti-dsDNA IgG and other autoantibodies, and develop age-dependent disease, which includes skin lesions and kidney pathology (2, 14, 49). In our female MRL/Faslpr/lpr mice, ANAs and anti-dsDNA IgG autoantibodies appeared at 6 wk of age and reached high levels at 12 wk, in association with significant loads of point mutations and DNA deletions in the IgH locus. At 17 wk, all of these mice showed severe kidney immunopathology, and 75% of them displayed various skin lesions, which, in 55% of the cases, included the characteristic “butterfly” rash. To determine whether HDIs could inhibit the lupus class-switched and hypermutated autoantibody response, we assigned 80 3-wk-old female MRL/Faslpr/lpr mice to three groups: a “nontreatment” group consisting of 50 mice that were given untreated water throughout their lives; an “early treatment” group of 15 mice that were given untreated water for the first 6 wk of life, at which time they were started on HDI water; and, a “late treatment” group of 15 mice that were given untreated water for the first 17 wk of life, at which time they were started on HDI water.

At 12 wk of age, “early” HDI-treated MRL/Faslpr/lpr mice displayed reduced levels of anti-dsDNA IgG, IgG1, IgG2a, and ANA (data not shown), but not IgM, autoantibodies; reduced overall IgG1/IgG2a but not IgM; significantly reduced (by >75%) somatic point mutations, with no significant alteration in spectrum; and a reduced load of DNA deletions in the IgH locus (Figs. 9A, 9B, 10A, 10B, Supplemental Fig. 3). They also exhibited reduced numbers of IgG2a+ B cells, as well as reduced plasma cell differentiation, in the presence of normal B220+ cell proliferation and normal B and T cell numbers (Fig. 9C–E). Early treated MRL/Faslpr/lpr mice downregulated Aicda, Prdm1, and Xbp1, but not Ung, expression in B cells or plasma cells (Fig. 9F) and increased miR-155, miR-181b, miR-361, miR-23b, miR-30a, and miR-125 in B cells (irrelevant miR-19a/b, miR-20a, and miR-25 expression was unchanged) (Fig. 9G). This did not result from altered cell viability/apoptosis (Fig. 10C, 10D) or decreased expression of antiapoptotic genes (Fig. 10E, 10F). At 17 wk of age, “early” HDI-treated MRL/Faslpr/lpr mice showed reduced skin lesions, including absence of the “butterfly” rash, as well as reduced kidney pathology (Fig. 11A, 11B, 11D) and size of spleen and lymph nodes (data not shown). They also continued to show reduced ANA and anti-dsDNA IgG1/IgG2a autoantibodies (Fig. 11C, 11E). Decreased anti-dsDNA IgG, IgG1, and IgG2a (but not IgM) autoantibodies and amelioration of pathology (data not shown), in association with complete healing of extensive skin lesions, also were observed in the late treatment group of mice, which were started on HDI water at 17 wk, an age at which our MRL/Faslpr/lpr mice already showed significant anti-dsDNA IgG autoantibodies and disease (Fig. 11F–H). The reduced IgG autoantibody levels and disease activity in early and late HDI-treated mice resulted in a significantly extended lifespan (p < 0.0001), with 8 of the 15 early treated mice and 7 of the 15 late-treated mice still alive and apparently healthy at 40 wk of age. Only 1 of the 50 “nontreated” mice made it to 32 wk; this mouse died at 36 wk (Fig. 11I). Thus, in lupus-prone mice, HDIs upregulate selected miRNAs, which can silence B cell AID or Blimp-1 expression, thereby reducing CSR, SHM, and plasma cell differentiation and dampening the class-switched and hypermutated autoantibody response, immunopathology, and disease, significantly prolonging life.

FIGURE 9.

HDIs impair class-switched and hypermutated autoantibody response, increase selected miRNAs, and decrease target Aicda and Prdm1 mRNAs, as well as Xbp1 mRNA, in MRL/Faslpr/lpr mice. Female MRL/Faslpr/lpr mice were started on HDI water or untreated water at the age of 6 wk and analyzed at the age of 12 wk. (A) Titers of circulating anti-dsDNA IgM, IgG, IgG1, and IgG2a and total IgM, IgG1, and IgG2a (n ≥ 5 mice/group). (B) Frequency of somatic point mutations was reduced by 75% in MRL/Faslpr/lpr mice given HDI water. A 700-bp intronic JH4-iEμ DNA in CD19+PNAhi Peyer’s patch GC B cells was amplified and sequenced (sequence data were pooled from three mice in each group). Pie charts depict the proportions of sequences that carried 1, 2, 3, and so forth point mutations (center of pie shows the number of independent sequences analyzed). Listed below the pie charts are overall mutation frequencies (changes/base). (C) Proportions of IgG2a+ B cells and proliferation of spleen B220+ cells (analyzed by administration of BrdU in drinking water at 10 wk of age). (D) CD19loCD138+ plasma cells in spleens. Data are representative of three independent experiments. (E) Surface CD19 and CD3 expression in spleen cells. Data are from one of three independent experiments yielding comparable results. (F) Aicda and Ung transcripts (in spleen CD19+CD138 B cells, normalized to Cd79b transcript) and Prdm1 and Xbp1 transcripts (in spleen CD19loCD138+ plasma cells, normalized to Gapdh transcript) were measured by qRT-PCR. Values from mice that were on HDI water are depicted as relative to the expression of each transcript in mice that were on untreated water, set as 1. Data are mean and SEM from four independent experiments. (G) miRNA expression in CD19+CD138 spleen B cells was measured by qRT-PCR and normalized to expression of small nuclear/nucleolar RNAs RNU6-1/2, SNORD61, SNORD68, and SNORD70. miRNA expression in the B cells from mice that were on HDI water are depicted as relative to the expression of each miRNA in the B cells from mice that were on untreated water, set as 1. Data are mean and SEM from three independent experiments. The p values were determined using an unpaired t test.

FIGURE 9.

HDIs impair class-switched and hypermutated autoantibody response, increase selected miRNAs, and decrease target Aicda and Prdm1 mRNAs, as well as Xbp1 mRNA, in MRL/Faslpr/lpr mice. Female MRL/Faslpr/lpr mice were started on HDI water or untreated water at the age of 6 wk and analyzed at the age of 12 wk. (A) Titers of circulating anti-dsDNA IgM, IgG, IgG1, and IgG2a and total IgM, IgG1, and IgG2a (n ≥ 5 mice/group). (B) Frequency of somatic point mutations was reduced by 75% in MRL/Faslpr/lpr mice given HDI water. A 700-bp intronic JH4-iEμ DNA in CD19+PNAhi Peyer’s patch GC B cells was amplified and sequenced (sequence data were pooled from three mice in each group). Pie charts depict the proportions of sequences that carried 1, 2, 3, and so forth point mutations (center of pie shows the number of independent sequences analyzed). Listed below the pie charts are overall mutation frequencies (changes/base). (C) Proportions of IgG2a+ B cells and proliferation of spleen B220+ cells (analyzed by administration of BrdU in drinking water at 10 wk of age). (D) CD19loCD138+ plasma cells in spleens. Data are representative of three independent experiments. (E) Surface CD19 and CD3 expression in spleen cells. Data are from one of three independent experiments yielding comparable results. (F) Aicda and Ung transcripts (in spleen CD19+CD138 B cells, normalized to Cd79b transcript) and Prdm1 and Xbp1 transcripts (in spleen CD19loCD138+ plasma cells, normalized to Gapdh transcript) were measured by qRT-PCR. Values from mice that were on HDI water are depicted as relative to the expression of each transcript in mice that were on untreated water, set as 1. Data are mean and SEM from four independent experiments. (G) miRNA expression in CD19+CD138 spleen B cells was measured by qRT-PCR and normalized to expression of small nuclear/nucleolar RNAs RNU6-1/2, SNORD61, SNORD68, and SNORD70. miRNA expression in the B cells from mice that were on HDI water are depicted as relative to the expression of each miRNA in the B cells from mice that were on untreated water, set as 1. Data are mean and SEM from three independent experiments. The p values were determined using an unpaired t test.

Close modal
FIGURE 10.

Somatic point mutations and DNA deletions are significantly reduced in frequency, whereas the spectrum of point mutations is unaltered; viability and apoptosis of B cells and plasma cells are not altered in MRL/Faslpr/lpr mice treated with HDI. Female MRL/Faslpr/lpr mice were on HDI water or untreated water (from 6 to 12 wk of age, at which time the mice were sacrificed, as in Fig. 9 and Supplemental Fig. 3). (A and B) Point mutations and DNA deletions in intronic JH4-iEμ DNA sequences of Peyer’s patches CD19+PNAhi (GC) B cells. (A) The spectrum of the residual mutations is unchanged by HDI treatment. Values are expressed as the actual number of different nucleotide substitutions (upper panels) or as the percentage of total mutations (lower panels). (B) The number of IgH locus DNA deletions is greatly reduced in mice that were on HDI water. Pie charts depict the proportions of sequences that contain different sized deletions in the IgH locus. In the center is the number of independent sequences analyzed. Spleen cells from MRL/Faslpr/lpr mice that were on HDI water or untreated water were gated to analyze 7-AAD viable cells or annexin V+ apoptotic cells among CD19+C138 B cells (C) and CD19loCD138+ plasma cells (D). Expression of Bcl2, Mcl1, and Bcl2l1 transcripts in CD19+CD138 B cells (E) and CD19loCD138+ (F) plasma cells were measured by qRT-PCR and normalized to Gapdh expression. Values for the cells from mice that were on HDI water are depicted as relative to the expression of each transcript in the cells from mice that were on untreated water, set as 1. Data are mean and SEM from three independent experiments.

FIGURE 10.

Somatic point mutations and DNA deletions are significantly reduced in frequency, whereas the spectrum of point mutations is unaltered; viability and apoptosis of B cells and plasma cells are not altered in MRL/Faslpr/lpr mice treated with HDI. Female MRL/Faslpr/lpr mice were on HDI water or untreated water (from 6 to 12 wk of age, at which time the mice were sacrificed, as in Fig. 9 and Supplemental Fig. 3). (A and B) Point mutations and DNA deletions in intronic JH4-iEμ DNA sequences of Peyer’s patches CD19+PNAhi (GC) B cells. (A) The spectrum of the residual mutations is unchanged by HDI treatment. Values are expressed as the actual number of different nucleotide substitutions (upper panels) or as the percentage of total mutations (lower panels). (B) The number of IgH locus DNA deletions is greatly reduced in mice that were on HDI water. Pie charts depict the proportions of sequences that contain different sized deletions in the IgH locus. In the center is the number of independent sequences analyzed. Spleen cells from MRL/Faslpr/lpr mice that were on HDI water or untreated water were gated to analyze 7-AAD viable cells or annexin V+ apoptotic cells among CD19+C138 B cells (C) and CD19loCD138+ plasma cells (D). Expression of Bcl2, Mcl1, and Bcl2l1 transcripts in CD19+CD138 B cells (E) and CD19loCD138+ (F) plasma cells were measured by qRT-PCR and normalized to Gapdh expression. Values for the cells from mice that were on HDI water are depicted as relative to the expression of each transcript in the cells from mice that were on untreated water, set as 1. Data are mean and SEM from three independent experiments.

Close modal
FIGURE 11.

HDIs reduce autoantibodies, immunopathology, and disease symptoms and extend the lifespan of MRL/Faslpr/lpr mice. (AE) Female MRL/Faslpr/lpr mice were started on HDI water or untreated water at the age of 6 wk and analyzed at the age of 17 wk. (A) Rostral and dorsal images show characteristic lupus of skin lesion, including a “butterfly” rash. (B) Kidney pathology. Representative photomicrographs of kidney sections stained with H&E (left panels) or FITC-labeled rat mAb to mouse IgG1 and IgG2a (right panels). Scale bars, 100 μm. Data are from one of three independent experiments yielding similar results. (C) ANAs visualized by indirect immunofluorescence of HEp-2 cells that were incubated with sera (1:40 dilution) from MRL/Faslpr/lpr mice using FITC-labeled rat mAb to mouse IgG1 and IgG2a. Scale bars, 20 μm. Data are from one of three independent experiments yielding similar results. (D) Skin lesion score in MRL/Faslpr/lpr mice (n = 15; 11 of 15 untreated mice, but only 4 of 15 HDI-treated mice, developed skin lesions). (E) Titers of circulating anti-dsDNA IgG1 and IgG2a. (FI) Fifty female MRL/Faslpr/lpr mice were on untreated water throughout their lives; 15 female MRL/Faslpr/lpr mice were on untreated water for the first 6 wk of life, after which they were started on HDI water; and 15 female MRL/Faslpr/lpr mice were on untreated water for the first 17 wk of life, at which age they were showing active disease (skin lesions, proteinuria, anti-dsDNA autoantibodies) and were started on HDI water. (F) Dorsal images showing severe skin lesions in four female MRL/Faslpr/lpr mice before (upper panels, 17 wk of age) and after (lower panels, 21 wk of age) 4 wk of HDI administration. (G) Skin lesion scores in 15 female MRL/Faslpr/lpr mice before (17 wk of age) and after (21 wk of age) 4 wk of HDI administration. (H) Anti-dsDNA IgM, IgG, IgG1, and IgG2a autoantibody titers in female MRL/Faslpr/lpr mice before (17 wk of age) and after (21 wk of age) 4 wk of HDI administration. (I) Survival of 50 female MRL/Faslpr/lpr mice given untreated water throughout their lives (black line), 15 female MRL/Faslpr/lpr mice started on HDI water at 6 wk of age (blue line), and 15 female MRL/Faslpr/lpr mice started on HDI water at 17 wk of age when they already showed active disease (green line). The p values were determined using an unpaired t test.

FIGURE 11.

HDIs reduce autoantibodies, immunopathology, and disease symptoms and extend the lifespan of MRL/Faslpr/lpr mice. (AE) Female MRL/Faslpr/lpr mice were started on HDI water or untreated water at the age of 6 wk and analyzed at the age of 17 wk. (A) Rostral and dorsal images show characteristic lupus of skin lesion, including a “butterfly” rash. (B) Kidney pathology. Representative photomicrographs of kidney sections stained with H&E (left panels) or FITC-labeled rat mAb to mouse IgG1 and IgG2a (right panels). Scale bars, 100 μm. Data are from one of three independent experiments yielding similar results. (C) ANAs visualized by indirect immunofluorescence of HEp-2 cells that were incubated with sera (1:40 dilution) from MRL/Faslpr/lpr mice using FITC-labeled rat mAb to mouse IgG1 and IgG2a. Scale bars, 20 μm. Data are from one of three independent experiments yielding similar results. (D) Skin lesion score in MRL/Faslpr/lpr mice (n = 15; 11 of 15 untreated mice, but only 4 of 15 HDI-treated mice, developed skin lesions). (E) Titers of circulating anti-dsDNA IgG1 and IgG2a. (FI) Fifty female MRL/Faslpr/lpr mice were on untreated water throughout their lives; 15 female MRL/Faslpr/lpr mice were on untreated water for the first 6 wk of life, after which they were started on HDI water; and 15 female MRL/Faslpr/lpr mice were on untreated water for the first 17 wk of life, at which age they were showing active disease (skin lesions, proteinuria, anti-dsDNA autoantibodies) and were started on HDI water. (F) Dorsal images showing severe skin lesions in four female MRL/Faslpr/lpr mice before (upper panels, 17 wk of age) and after (lower panels, 21 wk of age) 4 wk of HDI administration. (G) Skin lesion scores in 15 female MRL/Faslpr/lpr mice before (17 wk of age) and after (21 wk of age) 4 wk of HDI administration. (H) Anti-dsDNA IgM, IgG, IgG1, and IgG2a autoantibody titers in female MRL/Faslpr/lpr mice before (17 wk of age) and after (21 wk of age) 4 wk of HDI administration. (I) Survival of 50 female MRL/Faslpr/lpr mice given untreated water throughout their lives (black line), 15 female MRL/Faslpr/lpr mice started on HDI water at 6 wk of age (blue line), and 15 female MRL/Faslpr/lpr mice started on HDI water at 17 wk of age when they already showed active disease (green line). The p values were determined using an unpaired t test.

Close modal

As we have argued, epigenetic changes, such as histone posttranslation modifications and DNA methylation, and epigenetic factors, such as miRNAs, can interact with genetic programs to regulate B cell functions, including CSR, SHM, and plasma cell differentiation, thereby informing Ab responses that are critical for the defense against microbial pathogens and tumor cells, as well as autoantibody responses that mediate autoimmunity and disease (3). We showed in this study that VPA and butyrate, two SCFA HDIs, inhibited CSR, SHM, and plasma cell differentiation by modulating intrinsic B cell mechanisms. They repressed AID and Blimp-1 expression in mouse and human B cells by upregulating selected miRNAs that silenced AICDA/Aicda and PRDM1/Prdm1 mRNAs, as demonstrated by multiple qRT-PCRs (this study) and further confirmed by mRNA-Seq and microRNA-Seq (H. Zan and P. Casali, unpublished observations). AID expression and CSR also were inhibited by TSA, a hydroxamic acid HDI. The doses at which VPA and butyrate inhibited B cell class switching, hypermutation, and plasma cell differentiation were within the range of those measured in humans for these HDIs (41, 43). By inhibiting AID and Blimp-1 expression, VPA dampened class-switched and hypermutated Abs in specific T-dependent and T-independent Ab responses in normal mice. This HDI also dampened class-switched and hypermutated autoantibody levels, reduced immunopathology, and extended survival in autoimmune MRL/Faslpr/lpr mice, a well-studied model of human lupus.

SCFA HDIs were suggested to display significant selectivity for different HDACs (58). For example, VPA targets class I HDACs, particularly HDAC1 and HDAC2, and, less effectively, class IIa HDACs; butyrate targets class I HDACs, mainly HDAC1, and, less effectively, other members of class I and class IIa HDACs (38, 39). HDAC activity is primarily associated with multiprotein complexes, the role and composition of which are often cell-type specific. HDAC-associated proteins specify the selectivity of HDIs, which display different affinities for different HDAC/cofactor complexes. HDIs with diverse chemical properties target different HDACs and HDAC/cofactor complexes, thereby regulating gene expression in a locus- and cell-type–specific fashion (58). Our findings indicate that, in B cells, HDIs modulate miRNAs selectively, possibly as a result of HDACs existing in unique contexts of HDAC/cofactor complexes, as occurring in these lymphocytes, particularly when in an activated state.

HDIs also may indirectly modulate Ab responses or mitigate autoimmunity by affecting elements other than B cells, such as innate immune cells (59) and T cells (regulatory T cells and Th1 and Th17 cells), or inhibiting proinflammatory cytokines (37, 46, 60, 61). However, as shown in this study, HDIs directly regulate B cell genes that are central to peripheral differentiation of these lymphocytes and maturation of Ab and autoantibody responses. Silencing AICDA/Aicda by HDIs was intrinsic to B lymphocytes and independent of other cellular elements, as shown by our in vitro experiments using purified human and mouse B cells, as well as our in vivo studies of the T-independent response to NP-LPS. In both in vivo and in vitro B cells, the HDI-mediated downregulation of AICDA/Aicda expression was associated with a concomitant increase in the respective targeting miR-155, miR-181b, and miR-361 (2), in a tight dose-dependent fashion. Our findings extend those suggesting a role for miR-155 in downregulating AID expression (28, 30, 62), in agreement with the demonstration that repression of this miRNA provides a mechanism of Bcl6-promoted positive regulation of AID and increased GC gene expression (30). As we showed, silencing of PRDM1/Prdm1 (and XBP1/Xbp1) by HDIs also was intrinsic to B cells and independent of other cells. Like for Aicda, HDI-mediated downregulation of PRDM1/Prdm1 was associated with a concomitant increase in the respective B cell–targeting miRNAs (miR-23b, miR-30a, and miR-125b) (2), in vivo and in vitro, and in a tight dose-dependent fashion. HDI-induced downregulation of XBP1/Xbp1 could be secondary to decreased Blimp-1 expression and/or upregulation of selected miRNAs that we tentatively identified as silencers of XBP1/Xbp1 (H. Zan and P. Casali, unpublished observations). That HDIs downregulate Blimp-1 expression by upregulating miR-23b, miR-30a, and miR-125b that silence Prdm1 was further supported by our demonstration that HDIs slightly reduced or did not essentially alter the Prdm1 repressor genes Bach2, Bcl6, or Pax5.

The selectivity of HDI-mediated silencing of AICDA/Aicda and PRDM1/Prdm1 in B cells was further emphasized by the unchanged expression of HoxC4, Irf4, Rev1, and Ung, which play important roles in AICDA/Aicda regulation and/or CSR, as well as of miR-19a/b, miR-20a, and miR-25, which are not known to regulate AICDA/Aicda or PRDM1/Prdm1. We could not rule out the possibility that HDI regulated other B cell factors (e.g., NF-κB or Id2/3), which contributed to the reduction in AID or Blimp-1. The decrease in HDI-mediated repression of luciferase activity under the control of Aicda and Prdm1 mRNA 3′UTRs bearing mutated miR-155, miR-181b, miR-23b, miR-30a, and miR-125b target sites demonstrated that miRNAs are indeed direct effectors of the HDI-mediated repression of such selected genes in B cells. The role of B cell miRNAs in mediating HDI suppression of AID and Blimp-1 expression, as well as in the dampening of Ab and autoantibody responses, could be further addressed using an integrated three-prong approach involving the generation of in vivo Argonaute–miRNA–Aicda or –Prdm1 mRNA ternary complexes, knock-in mice lacking specific miRNA-targeting sites in Aicda or Prdm1 3′UTR, or mice with B cells specifically expressing “sponge” inhibitors of miR-155, miR-181b and miR-361, or miR-23b, miR-30a, and miR-125b. HDIs had no direct effect on the epigenetic status of the Aicda locus, because our acetylated histone ChIP and bisulfite sequencing experiments showed no alteration in histone acetylation or methylation of the Aicda promoter by VPA. Although it is possible that HDIs could also modify protein functions by increasing acetylation of nonchromatin proteins, our findings allow us to conclude that modulation of miRNAs leading to silencing of selected mRNAs is the mechanism by which HDIs mediate inhibition of the B cell differentiation processes that underpin the maturation of Ab responses.

Our findings in human and mouse B cells, in vitro and in vivo, greatly extend and provide a mechanistic underpinning for the limited data by Kienzler et al., suggesting that VPA reduces human naive B cell differentiation to (CD27hiCD38hi) plasmablasts and reduces IgG and IgA expression. However, at odds with our findings, they did not observe a decrease in CSR induction in human B cells in vitro by VPA. This could be explained by the different designs of their experiments compared with ours. Kienzler et al. (63) stimulated human B cells with CD154 + IL-21; we stimulated human naive B cells with CD154 + IL-21 + IL-4 or CD154 + IL-21 + TGF-β. IL-4 or TGF-β, both critical CSR-inducing stimuli, were missing in Kienzler et al.’s experiments, possibly resulting in relatively lower AICDA and PRDM1 expression. Analysis of the molecular events underpinning CSR was also missing, making it virtually impossible to provide a thorough explanation for the putative discrepancy between the data of Kienzler et al. and ours.

In vivo HDI inhibition of CSR and plasma cell differentiation “freezes” B cells at an IgM+ stage, as indicated by the higher proportion of IgM+ lymphocytes in human or mouse B cell cultures exposed to HDIs. Whether these IgM+ B cells remained “naive” B cells or underwent some degree of memory B cell differentiation is unclear. The much-reduced IgH locus mutational load in HDI-treated normal and lupus-prone mice supports the contention that those IgM+ B cells expressed primarily unmutated IgM natural Abs. These still would have been available for the response to microbial pathogens and might have played a protective role in systemic autoimmunity (64). In addition, in both normal and autoimmune mice, HDI treatment allowed for some residual AID expression, which resulted in a significant reduction in, but not ablation of, secondary Ab isotypes. Even at low titers, these can mediate a protective antimicrobial immunity, as suggested by the apparently normal risk for infections in Aicda+/− mice with reduced AID levels (65). Thus, in normal and autoimmune mice, HDIs dampen the Ab or autoantibody response by efficiently inhibiting CSR, SHM, and plasma cell differentiation, while leaving an intact or even increased IgM pool, as well as residual IgG and IgA levels that may be sufficient for immune protection.

At higher doses than those used in our study, HDIs inhibit proliferation and induce apoptosis in cancer cells (66). They do so partially through induction of DNA damage, which healthy cells can repair but cancer cells cannot (67). In our in vitro and in vivo experiments, even the highest HDI doses did not reduce B cell and plasma cell viability or increase B cell or plasma cell apoptosis. Consistent with a recent finding that butyrate did not affect survival or proliferation of T cells (42), this SCFA HDI did not affect viability or proliferation of B lymphocytes at the concentrations used in this study. Similarly, VPA did not affect B cell viability, proliferation, cell cycle, or apoptosis, nor did it affect viability or survival of plasma cells. The reduction in the proportion of class-switched B cells/round of cell division (which is required for CSR) in the context of an unchanged overall cell number at each division further indicated that HDIs inhibited CSR without interfering with cell viability. This is consistent with the normal levels of lymphocytes in patients treated with VPA (46), in whom lymphopenia would have been expected to occur if this HDI impaired B and/or T cell viability.

Epigenetic dysregulation can compound genetic susceptibility to mediate autoantibody responses and autoimmunity (3). Epigenetic changes associated with autoimmune responses have been investigated in T cells but only marginally in B cells (68). We (14) and other investigators (69) showed that highly upregulated AID and Blimp-1 expression is an important feature of lupus patients and lupus-prone mice, including MRL/Faslpr/lpr mice. In these mice, dysregulation of AID and Blimp-1 causes aberrant rates of CSR and SHM, leading to increased loads of somatic point mutations and deletions/insertions in the IgH locus, as well as heightened Ig-secretion rates that result in abundant production of pathogenic autoantibodies. Accordingly, increased AID and Blimp-1 expression in lupus patients is associated with high levels of mutated IgG autoantibodies, which heighten disease activity (14, 69). Conversely, AID deficiency in MRL/Faslpr/lpr Aicda−/− mice protected against disease (64, 70), and decreased AID expression in MRL/Faslpr/lpr HoxC4−/− and MRL/Faslpr/lpr Aicda+/− mice, which display 30–60% of the AID level of MRL/Faslpr/lpr Aicda+/+ mice, reduced autoantibody titers and delayed disease (14, 71). A role in promoting GC formation and generation of class-switched autoantibodies was suggested for miR-155 (62, 72, 73), and reduced autoantibody production and autoimmunity were reported in miR-155–deficient B6/Faslpr/lpr mice (74). However, this likely resulted from dysregulation of a variety of genes in multiple immune cells, including derepressed expression of SHIP-1 in B cells, which led to mitigation of B cell activation, proliferation, and autoantibody production. In our hands, HDIs did not yield obvious alterations in GC formation or B cell SHIP-1 transcripts (data not shown).

PRDM1 has been identified as one of the risk loci for lupus in human genetic-association studies (75, 76), and increased Blimp-1 expression was shown to parallel a surge in circulating plasma cells during disease flares (77). Blimp-1 is required for generation of short-lived and long-lived plasma cells. Unlike short-lived plasma cells, long-lived autoreactive, malignant, or allergen-specific (IgE+) plasma cells are refractory to immunosuppression and irradiation (78). In our MRL/Faslpr/lpr mice, HDI-mediated upregulation of miR-30a and miR-125b, which are highly expressed in GC B cells and downregulated in plasma cells (32, 79), along with HDI-mediated upregulation of miR-23b, which is reduced in lupus (80), silenced Blimp-1 expression, thereby impairing plasma cell differentiation and compounding the negative effect of decreased CSR and SHM on the production of high-affinity class-switched autoantibodies. Because Blimp-1 is required for formation and maintenance of plasma cells (4), HDI-mediated downregulation of Blimp-1 can lead to significantly long-lasting lower levels of autoantibodies by decreasing autoantibody-producing plasma cells. Accordingly, our preliminary data (data not shown) suggest that the beneficial effect of HDIs is long lasting after withdrawal of the drug from treated autoimmune mice.

Butyrate is one of the SCFAs produced by gut commensal bacteria through dietary fiber fermentation (41) and is the most potent HDI among the SCFAs. It modulates the function of intestinal macrophages (81) and acts on naive T cells to promote epigenetic changes that regulate the expression of genes responsible for differentiation into regulatory T cells and IL-10–producing T cells (42, 82). Our demonstration that butyrate (at a dose as low as 250 μM) modulates AID expression and CSR to IgG, IgA, and IgE, as well as plasma cell differentiation through direct activity on B cells, indicates that this HDI can play an important role in modulating Ab responses of gut lymphoid organs (in which butyrate occurs at 1–20 mM). This would be particularly true of the cecal patch, a major intestinal lymphoid organ in the proximal colon, as well as in Peyer’s patches, which are highly represented in the ileum, the portion of intestine that is immediately afferent to the proximal colon. Both the cecal patch and Peyer’s patches contain vast numbers of B cells committed to the production of IgA, and to a lesser extent, IgE (83, 84). Butyrate may also play an important role in limiting AID expression in the inflamed colonic mucosa, in which AID is induced by proinflammatory cytokines (85). By suppressing AID, butyrate could suppress inflammation-mediated neoplastic transformation, leading to colorectal cancer (86), a process in which AID-mediated oncogenic mutagenesis plays a significant role.

Metabolites from intestinal microbiota are key determinants of host–microbe mutualism and, consequently, the health or disease of the intestinal tract, as well as other organs and tissues (8789). It was suggested that SCFAs produced by gut commensal bacteria can distribute systemically and shape the immunological environment in the lung, thereby influencing the severity of allergic inflammation. Mice fed a high-fiber diet had increased circulating levels of SCFAs and were protected against allergic inflammation (mediated by IgE) of the lung, whereas a low-fiber diet decreased levels of SCFAs and increased allergic airway disease (87). A diverse microbial population, which would produce an appropriate amount of SCFA HDIs, particularly, butyrate, is required to maintain a baseline immune-regulatory state, including IgG, IgA, and IgE levels. Elevated serum IgE and CSR to IgE in B cells at mucosal sites in the absence of microbial colonization in germ-free mice and in mice with low-diversity gut microbiota further emphasize the important role for gut commensal bacteria–produced butyrate in modulating IgE levels (90, 91). Altered composition and decreased bacterial diversity of gut microbiota would lead to changes in absolute and relative levels of SCFA HDIs (89) and, therefore, changes in systemic IgG, IgA, and IgE specificities and levels, which contribute to altered immunity and increased susceptibility to immune-mediated diseases.

Despite involving no human patient, our study provides a strong rationale and a mechanistic basis for the use of HDIs as epigenetic modulators of Ab responses, as well as therapeutics for systemic autoimmunity and, possibly, IgE-mediated allergic responses. In our experiments, HDI was administered in drinking water, rather than parenterally as in previous studies (46), resulting in steady and well-tolerated therapeutic levels of HDIs. These were comparable to those in patients taking HDIs per os (43) and without the concentration spikes associated with HDI injections (46). HDI administration in drinking water likely contributed to the effectiveness of the modulation of T-dependent and T-independent Ab responses in healthy mice, as well as to the dampening of the systemic autoantibody response, reduction in immunopathology, and extended survival in lupus mice. Overall, our studies suggest a new and important therapeutic indication for VPA and butyrate, and, likely, other HDIs, such as TSA and suberoylanilide hydroxamic acid (approved by the U.S. Food and Drug Administration for the treatment of cutaneous T cell lymphoma). They also provide novel and significant mechanistic insights into epigenetic mechanisms of immunoregulation, as mediated by direct modulation of B cell–intrinsic functions, thereby offering new clues for further therapeutic approaches, as specifically targeted to B cells.

This paper is dedicated to the memory of our wonderful friend, Mr. Vic Braden. We thank Christie Mortales, Julia Taylor, Isabella Stenmark, Sonia Aghera, and Eun Jee Kim for assistance in performing some experiments and Dr. Irene Pederson for the pMIR-REPORT luciferase vector.

This work was supported by National Institutes of Health Grants AI079705, AI105813, and AI060573 (to P.C.), Alliance for Lupus Research Target Identification in Lupus Grant ALR 295955 (to P.C.), and the Arthritis National Research Foundation (to H.Z.). H.Z. is a Kelly Braden Memorial Fellow.

The online version of this article contains supplemental material.

Abbreviations used in this article:

7-AAD

7-aminoactinomycin D

AID

activation-induced cytidine deaminase

ANA

anti-nuclear Ab

Blimp-1

B lymphocyte–induced maturation protein-1

CH

constant H chain

ChIP

chromatin immunoprecipitation

CSR

class switch DNA recombination

FBS-RPMI

RPMI 1640 medium with 10% FBS, 50 mM 2-ME, and 1× antibiotic-antimycotic mixture

GC

germinal center

HDAC

histone deacetylase

HDI

HDAC inhibitor

IH

intervening region of CH gene

miRNA

microRNA

mut

mutant

PNA

peanut agglutinin

qPCR

quantitative PCR

qRT-PCR

quantitative RT-PCR

RU

relative unit

SCFA

short-chain fatty acid

SHM

somatic hypermutation

TSA

trichostatin A

UTR

untranslated region

VPA

valproic acid

Xbp-1

X-box–binding protein 1.

1
Xu
Z.
,
Zan
H.
,
Pone
E. J.
,
Mai
T.
,
Casali
P.
.
2012
.
Immunoglobulin class-switch DNA recombination: induction, targeting and beyond.
Nat. Rev. Immunol.
12
:
517
531
.
2
Zan
H.
,
Casali
P.
.
2013
.
Regulation of Aicda expression and AID activity.
Autoimmunity
46
:
83
101
.
3
Li
G.
,
Zan
H.
,
Xu
Z.
,
Casali
P.
.
2013
.
Epigenetics of the antibody response.
Trends Immunol.
34
:
460
470
.
4
Martins
G.
,
Calame
K.
.
2008
.
Regulation and functions of Blimp-1 in T and B lymphocytes.
Annu. Rev. Immunol.
26
:
133
169
.
5
Liu
M.
,
Duke
J. L.
,
Richter
D. J.
,
Vinuesa
C. G.
,
Goodnow
C. C.
,
Kleinstein
S. H.
,
Schatz
D. G.
.
2008
.
Two levels of protection for the B cell genome during somatic hypermutation.
Nature
451
:
841
845
.
6
Liu
M.
,
Schatz
D. G.
.
2009
.
Balancing AID and DNA repair during somatic hypermutation.
Trends Immunol.
30
:
173
181
.
7
He
B.
,
Santamaria
R.
,
Xu
W.
,
Cols
M.
,
Chen
K.
,
Puga
I.
,
Shan
M.
,
Xiong
H.
,
Bussel
J. B.
,
Chiu
A.
, et al
.
2010
.
The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88.
Nat. Immunol.
11
:
836
845
.
8
Pone
E. J.
,
Xu
Z.
,
White
C. A.
,
Zan
H.
,
Casali
P.
.
2012
.
B cell TLRs and induction of immunoglobulin class-switch DNA recombination.
Front Biosci (Landmark Ed)
17
:
2594
2615
.
9
Pone
E. J.
,
Zhang
J.
,
Mai
T.
,
White
C. A.
,
Li
G.
,
Sakakura
J. K.
,
Patel
P. J.
,
Al-Qahtani
A.
,
Zan
H.
,
Xu
Z.
,
Casali
P.
.
2012
.
BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway.
Nat. Commun.
3
:
767
.
10
Cerutti
A.
,
Cols
M.
,
Puga
I.
.
2013
.
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes.
Nat. Rev. Immunol.
13
:
118
132
.
11
Sayegh
C. E.
,
Quong
M. W.
,
Agata
Y.
,
Murre
C.
.
2003
.
E-proteins directly regulate expression of activation-induced deaminase in mature B cells.
Nat. Immunol.
4
:
586
593
.
12
Park
S. R.
,
Zan
H.
,
Pal
Z.
,
Zhang
J.
,
Al-Qahtani
A.
,
Pone
E. J.
,
Xu
Z.
,
Mai
T.
,
Casali
P.
.
2009
.
HoxC4 binds to the promoter of the cytidine deaminase AID gene to induce AID expression, class-switch DNA recombination and somatic hypermutation.
Nat. Immunol.
10
:
540
550
.
13
Mai
T.
,
Zan
H.
,
Zhang
J.
,
Hawkins
J. S.
,
Xu
Z.
,
Casali
P.
.
2010
.
Estrogen receptors bind to and activate the HOXC4/HoxC4 promoter to potentiate HoxC4-mediated activation-induced cytosine deaminase induction, immunoglobulin class switch DNA recombination, and somatic hypermutation.
J. Biol. Chem.
285
:
37797
37810
.
14
White
C. A.
,
Seth Hawkins
J.
,
Pone
E. J.
,
Yu
E. S.
,
Al-Qahtani
A.
,
Mai
T.
,
Zan
H.
,
Casali
P.
.
2011
.
AID dysregulation in lupus-prone MRL/Faslpr/lpr mice increases class switch DNA recombination and promotes interchromosomal c-Myc/IgH loci translocations: modulation by HoxC4.
Autoimmunity
44
:
585
598
.
15
Li
G.
,
White
C. A.
,
Lam
T.
,
Pone
E. J.
,
Tran
D. C.
,
Hayama
K. L.
,
Zan
H.
,
Xu
Z.
,
Casali
P.
.
2013
.
Combinatorial H3K9acS10ph histone modification in IgH locus S regions targets 14-3-3 adaptors and AID to specify antibody class-switch DNA recombination.
Cell Reports
5
:
702
714
.
16
Shaffer
A. L.
,
Shapiro-Shelef
M.
,
Iwakoshi
N. N.
,
Lee
A. H.
,
Qian
S. B.
,
Zhao
H.
,
Yu
X.
,
Yang
L.
,
Tan
B. K.
,
Rosenwald
A.
, et al
.
2004
.
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation.
Immunity
21
:
81
93
.
17
Crotty
S.
,
Johnston
R. J.
,
Schoenberger
S. P.
.
2010
.
Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation.
Nat. Immunol.
11
:
114
120
.
18
Zan
H.
,
Tat
C.
,
Casali
P.
.
2014
.
MicroRNAs in lupus.
Autoimmunity
47
:
272
285
.
19
Fujimura
S.
,
Matsui
T.
,
Kuwahara
K.
,
Maeda
K.
,
Sakaguchi
N.
.
2008
.
Germinal center B-cell-associated DNA hypomethylation at transcriptional regions of the AID gene.
Mol. Immunol.
45
:
1712
1719
.
20
Crouch
E. E.
,
Li
Z.
,
Takizawa
M.
,
Fichtner-Feigl
S.
,
Gourzi
P.
,
Montaño
C.
,
Feigenbaum
L.
,
Wilson
P.
,
Janz
S.
,
Papavasiliou
F. N.
,
Casellas
R.
.
2007
.
Regulation of AID expression in the immune response.
J. Exp. Med.
204
:
1145
1156
.
21
Taganov
K. D.
,
Boldin
M. P.
,
Baltimore
D.
.
2007
.
MicroRNAs and immunity: tiny players in a big field.
Immunity
26
:
133
137
.
22
Koralov
S. B.
,
Muljo
S. A.
,
Galler
G. R.
,
Krek
A.
,
Chakraborty
T.
,
Kanellopoulou
C.
,
Jensen
K.
,
Cobb
B. S.
,
Merkenschlager
M.
,
Rajewsky
N.
,
Rajewsky
K.
.
2008
.
Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage.
Cell
132
:
860
874
.
23
Belver
L.
,
de Yébenes
V. G.
,
Ramiro
A. R.
.
2010
.
MicroRNAs prevent the generation of autoreactive antibodies.
Immunity
33
:
713
722
.
24
Kuchen
S.
,
Resch
W.
,
Yamane
A.
,
Kuo
N.
,
Li
Z.
,
Chakraborty
T.
,
Wei
L.
,
Laurence
A.
,
Yasuda
T.
,
Peng
S.
, et al
.
2010
.
Regulation of microRNA expression and abundance during lymphopoiesis.
Immunity
32
:
828
839
.
25
de Yébenes
V. G.
,
Bartolomé-Izquierdo
N.
,
Ramiro
A. R.
.
2013
.
Regulation of B-cell development and function by microRNAs.
Immunol. Rev.
253
:
25
39
.
26
Turner
M.
,
Galloway
A.
,
Vigorito
E.
.
2014
.
Noncoding RNA and its associated proteins as regulatory elements of the immune system.
Nat. Immunol.
15
:
484
491
.
27
Teng
G.
,
Hakimpour
P.
,
Landgraf
P.
,
Rice
A.
,
Tuschl
T.
,
Casellas
R.
,
Papavasiliou
F. N.
.
2008
.
MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase.
Immunity
28
:
621
629
.
28
Dorsett
Y.
,
McBride
K. M.
,
Jankovic
M.
,
Gazumyan
A.
,
Thai
T. H.
,
Robbiani
D. F.
,
Di Virgilio
M.
,
Reina San-Martin
B.
,
Heidkamp
G.
,
Schwickert
T. A.
, et al
.
2008
.
MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation.
Immunity
28
:
630
638
.
29
de Yébenes
V. G.
,
Belver
L.
,
Pisano
D. G.
,
González
S.
,
Villasante
A.
,
Croce
C.
,
He
L.
,
Ramiro
A. R.
.
2008
.
miR-181b negatively regulates activation-induced cytidine deaminase in B cells.
J. Exp. Med.
205
:
2199
2206
.
30
Basso
K.
,
Schneider
C.
,
Shen
Q.
,
Holmes
A. B.
,
Setty
M.
,
Leslie
C.
,
Dalla-Favera
R.
.
2012
.
BCL6 positively regulates AID and germinal center gene expression via repression of miR-155.
J. Exp. Med.
209
:
2455
2465
.
31
Wang
X.
,
Wang
K.
,
Han
L.
,
Zhang
A.
,
Shi
Z.
,
Zhang
K.
,
Zhang
H.
,
Yang
S.
,
Pu
P.
,
Shen
C.
, et al
.
2013
.
PRDM1 is directly targeted by miR-30a-5p and modulates the Wnt/β-catenin pathway in a Dkk1-dependent manner during glioma growth.
Cancer Lett.
331
:
211
219
.
32
Gururajan
M.
,
Haga
C. L.
,
Das
S.
,
Leu
C. M.
,
Hodson
D.
,
Josson
S.
,
Turner
M.
,
Cooper
M. D.
.
2010
.
MicroRNA 125b inhibition of B cell differentiation in germinal centers.
Int. Immunol.
22
:
583
592
.
33
Rossi
R. L.
,
Rossetti
G.
,
Wenandy
L.
,
Curti
S.
,
Ripamonti
A.
,
Bonnal
R. J.
,
Birolo
R. S.
,
Moro
M.
,
Crosti
M. C.
,
Gruarin
P.
, et al
.
2011
.
Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b.
Nat. Immunol.
12
:
796
803
.
34
Nambu
Y.
,
Sugai
M.
,
Gonda
H.
,
Lee
C. G.
,
Katakai
T.
,
Agata
Y.
,
Yokota
Y.
,
Shimizu
A.
.
2003
.
Transcription-coupled events associating with immunoglobulin switch region chromatin.
Science
302
:
2137
2140
.
35
Wang
L.
,
Wuerffel
R.
,
Feldman
S.
,
Khamlichi
A. A.
,
Kenter
A. L.
.
2009
.
S region sequence, RNA polymerase II, and histone modifications create chromatin accessibility during class switch recombination.
J. Exp. Med.
206
:
1817
1830
.
36
Delcuve
G. P.
,
Khan
D. H.
,
Davie
J. R.
.
2012
.
Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors.
Clin. Epigenetics
4
:
5
.
37
Reilly
C. M.
,
Regna
N.
,
Mishra
N.
.
2011
.
HDAC inhibition in lupus models.
Mol. Med.
17
:
417
425
.
38
Göttlicher
M.
,
Minucci
S.
,
Zhu
P.
,
Krämer
O. H.
,
Schimpf
A.
,
Giavara
S.
,
Sleeman
J. P.
,
Lo Coco
F.
,
Nervi
C.
,
Pelicci
P. G.
,
Heinzel
T.
.
2001
.
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.
EMBO J.
20
:
6969
6978
.
39
Davie
J. R.
2003
.
Inhibition of histone deacetylase activity by butyrate.
J. Nutr.
133
(
7
,
Suppl.
)
2485S
2493S
.
40
Phiel
C. J.
,
Zhang
F.
,
Huang
E. Y.
,
Guenther
M. G.
,
Lazar
M. A.
,
Klein
P. S.
.
2001
.
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
J. Biol. Chem.
276
:
36734
36741
.
41
Topping
D. L.
,
Clifton
P. M.
.
2001
.
Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides.
Physiol. Rev.
81
:
1031
1064
.
42
Furusawa
Y.
,
Obata
Y.
,
Fukuda
S.
,
Endo
T. A.
,
Nakato
G.
,
Takahashi
D.
,
Nakanishi
Y.
,
Uetake
C.
,
Kato
K.
,
Kato
T.
, et al
.
2013
.
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.
Nature
504
:
446
450
.
43
Atmaca
A.
,
Al-Batran
S. E.
,
Maurer
A.
,
Neumann
A.
,
Heinzel
T.
,
Hentsch
B.
,
Schwarz
S. E.
,
Hövelmann
S.
,
Göttlicher
M.
,
Knuth
A.
,
Jäger
E.
.
2007
.
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Br. J. Cancer
97
:
177
182
.
44
Münster
P.
,
Marchion
D.
,
Bicaku
E.
,
Schmitt
M.
,
Lee
J. H.
,
DeConti
R.
,
Simon
G.
,
Fishman
M.
,
Minton
S.
,
Garrett
C.
, et al
.
2007
.
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
J. Clin. Oncol.
25
:
1979
1985
.
45
Pone
E. J.
,
Zan
H.
,
Zhang
J.
,
Al-Qahtani
A.
,
Xu
Z.
,
Casali
P.
.
2010
.
Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses.
Crit. Rev. Immunol.
30
:
1
29
.
46
Dowdell
K. C.
,
Pesnicak
L.
,
Hoffmann
V.
,
Steadman
K.
,
Remaley
A. T.
,
Cohen
J. I.
,
Straus
S. E.
,
Rao
V. K.
.
2009
.
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas-deficient MRL/lpr-/- murine model of autoimmune lymphoproliferative syndrome (ALPS).
Exp. Hematol.
37
:
487
494
.
47
Wesemann
D. R.
,
Magee
J. M.
,
Boboila
C.
,
Calado
D. P.
,
Gallagher
M. P.
,
Portuguese
A. J.
,
Manis
J. P.
,
Zhou
X.
,
Recher
M.
,
Rajewsky
K.
, et al
.
2011
.
Immature B cells preferentially switch to IgE with increased direct Sμ to Sε recombination.
J. Exp. Med.
208
:
2733
2746
.
48
Zan
H.
,
White
C. A.
,
Thomas
L. M.
,
Mai
T.
,
Li
G.
,
Xu
Z.
,
Zhang
J.
,
Casali
P.
.
2012
.
Rev1 recruits ung to switch regions and enhances du glycosylation for immunoglobulin class switch DNA recombination.
Cell Reports
2
:
1220
1232
.
49
Zan
H.
,
Zhang
J.
,
Ardeshna
S.
,
Xu
Z.
,
Park
S. R.
,
Casali
P.
.
2009
.
Lupus-prone MRL/faslpr/lpr mice display increased AID expression and extensive DNA lesions, comprising deletions and insertions, in the immunoglobulin locus: concurrent upregulation of somatic hypermutation and class switch DNA recombination.
Autoimmunity
42
:
89
103
.
50
Xu
Z.
,
Fulop
Z.
,
Wu
G.
,
Pone
E. J.
,
Zhang
J.
,
Mai
T.
,
Thomas
L. M.
,
Al-Qahtani
A.
,
White
C. A.
,
Park
S. R.
, et al
.
2010
.
14-3-3 adaptor proteins recruit AID to 5′-AGCT-3′-rich switch regions for class switch recombination.
Nat. Struct. Mol. Biol.
17
:
1124
1135
.
51
González-García
I.
,
Ocaña
E.
,
Jiménez-Gómez
G.
,
Campos-Caro
A.
,
Brieva
J. A.
.
2006
.
Immunization-induced perturbation of human blood plasma cell pool: progressive maturation, IL-6 responsiveness, and high PRDI-BF1/BLIMP1 expression are critical distinctions between antigen-specific and nonspecific plasma cells.
J. Immunol.
176
:
4042
4050
.
52
Tunyaplin
C.
,
Shaffer
A. L.
,
Angelin-Duclos
C. D.
,
Yu
X.
,
Staudt
L. M.
,
Calame
K. L.
.
2004
.
Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation.
J. Immunol.
173
:
1158
1165
.
53
Basso
K.
,
Dalla-Favera
R.
.
2010
.
BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.
Adv. Immunol.
105
:
193
210
.
54
Ochiai
K.
,
Maienschein-Cline
M.
,
Simonetti
G.
,
Chen
J.
,
Rosenthal
R.
,
Brink
R.
,
Chong
A. S.
,
Klein
U.
,
Dinner
A. R.
,
Singh
H.
,
Sciammas
R.
.
2013
.
Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4.
Immunity
38
:
918
929
.
55
Ochiai
K.
,
Katoh
Y.
,
Ikura
T.
,
Hoshikawa
Y.
,
Noda
T.
,
Karasuyama
H.
,
Tashiro
S.
,
Muto
A.
,
Igarashi
K.
.
2006
.
Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells.
J. Biol. Chem.
281
:
38226
38234
.
56
Yasuda
T.
,
Hayakawa
F.
,
Kurahashi
S.
,
Sugimoto
K.
,
Minami
Y.
,
Tomita
A.
,
Naoe
T.
.
2012
.
B cell receptor-ERK1/2 signal cancels PAX5-dependent repression of BLIMP1 through PAX5 phosphorylation: a mechanism of antigen-triggering plasma cell differentiation.
J. Immunol.
188
:
6127
6134
.
57
Arzenani
M. K.
,
Zade
A. E.
,
Ming
Y.
,
Vijverberg
S. J.
,
Zhang
Z.
,
Khan
Z.
,
Sadique
S.
,
Kallenbach
L.
,
Hu
L.
,
Vukojević
V.
,
Ekström
T. J.
.
2011
.
Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics.
Mol. Cell. Biol.
31
:
4119
4128
.
58
Bantscheff
M.
,
Hopf
C.
,
Savitski
M. M.
,
Dittmann
A.
,
Grandi
P.
,
Michon
A. M.
,
Schlegl
J.
,
Abraham
Y.
,
Becher
I.
,
Bergamini
G.
, et al
.
2011
.
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.
Nat. Biotechnol.
29
:
255
265
.
59
Roger
T.
,
Lugrin
J.
,
Le Roy
D.
,
Goy
G.
,
Mombelli
M.
,
Koessler
T.
,
Ding
X. C.
,
Chanson
A. L.
,
Reymond
M. K.
,
Miconnet
I.
, et al
.
2011
.
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.
Blood
117
:
1205
1217
.
60
Villagra
A.
,
Sotomayor
E. M.
,
Seto
E.
.
2010
.
Histone deacetylases and the immunological network: implications in cancer and inflammation.
Oncogene
29
:
157
173
.
61
Akimova
T.
,
Beier
U. H.
,
Liu
Y.
,
Wang
L.
,
Hancock
W. W.
.
2012
.
Histone/protein deacetylases and T-cell immune responses.
Blood
119
:
2443
2451
.
62
Vigorito
E.
,
Perks
K. L.
,
Abreu-Goodger
C.
,
Bunting
S.
,
Xiang
Z.
,
Kohlhaas
S.
,
Das
P. P.
,
Miska
E. A.
,
Rodriguez
A.
,
Bradley
A.
, et al
.
2007
.
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells.
Immunity
27
:
847
859
.
63
Kienzler
A. K.
,
Rizzi
M.
,
Reith
M.
,
Nutt
S. L.
,
Eibel
H.
.
2013
.
Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid.
J. Allergy Clin. Immunol.
131
:
1695
1699
.
64
Jiang
C.
,
Zhao
M. L.
,
Scearce
R. M.
,
Diaz
M.
.
2011
.
Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
Arthritis Rheum.
63
:
1086
1096
.
65
Harada
Y.
,
Muramatsu
M.
,
Shibata
T.
,
Honjo
T.
,
Kuroda
K.
.
2003
.
Unmutated immunoglobulin M can protect mice from death by influenza virus infection.
J. Exp. Med.
197
:
1779
1785
.
66
Tang
J.
,
Yan
H.
,
Zhuang
S.
.
2013
.
Histone deacetylases as targets for treatment of multiple diseases.
Clin. Sci.
124
:
651
662
.
67
Lee
J. H.
,
Choy
M. L.
,
Ngo
L.
,
Foster
S. S.
,
Marks
P. A.
.
2010
.
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Proc. Natl. Acad. Sci. USA
107
:
14639
14644
.
68
Hedrich
C. M.
,
Tsokos
G. C.
.
2011
.
Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases.
Trends Mol. Med.
17
:
714
724
.
69
Luo
J.
,
Niu
X.
,
Liu
H.
,
Zhang
M.
,
Chen
M.
,
Deng
S.
.
2013
.
Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Mol. Immunol.
56
:
574
582
.
70
Jiang
C.
,
Foley
J.
,
Clayton
N.
,
Kissling
G.
,
Jokinen
M.
,
Herbert
R.
,
Diaz
M.
.
2007
.
Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice.
J. Immunol.
178
:
7422
7431
.
71
Jiang
C.
,
Zhao
M. L.
,
Diaz
M.
.
2009
.
Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis.
Immunology
126
:
102
113
.
72
Rodriguez
A.
,
Vigorito
E.
,
Clare
S.
,
Warren
M. V.
,
Couttet
P.
,
Soond
D. R.
,
van Dongen
S.
,
Grocock
R. J.
,
Das
P. P.
,
Miska
E. A.
, et al
.
2007
.
Requirement of bic/microRNA-155 for normal immune function.
Science
316
:
608
611
.
73
Thai
T. H.
,
Calado
D. P.
,
Casola
S.
,
Ansel
K. M.
,
Xiao
C.
,
Xue
Y.
,
Murphy
A.
,
Frendewey
D.
,
Valenzuela
D.
,
Kutok
J. L.
, et al
.
2007
.
Regulation of the germinal center response by microRNA-155.
Science
316
:
604
608
.
74
Thai
T. H.
,
Patterson
H. C.
,
Pham
D. H.
,
Kis-Toth
K.
,
Kaminski
D. A.
,
Tsokos
G. C.
.
2013
.
Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas(lpr) mouse.
Proc. Natl. Acad. Sci. USA
110
:
20194
20199
.
75
Odendahl
M.
,
Jacobi
A.
,
Hansen
A.
,
Feist
E.
,
Hiepe
F.
,
Burmester
G. R.
,
Lipsky
P. E.
,
Radbruch
A.
,
Dörner
T.
.
2000
.
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus.
J. Immunol.
165
:
5970
5979
.
76
Gateva
V.
,
Sandling
J. K.
,
Hom
G.
,
Taylor
K. E.
,
Chung
S. A.
,
Sun
X.
,
Ortmann
W.
,
Kosoy
R.
,
Ferreira
R. C.
,
Nordmark
G.
, et al
.
2009
.
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus.
Nat. Genet.
41
:
1228
1233
.
77
Guerra
S. G.
,
Vyse
T. J.
,
Cunninghame Graham
D. S.
.
2012
.
The genetics of lupus: a functional perspective.
Arthritis Res. Ther.
14
:
211
.
78
Hiepe
F.
,
Dörner
T.
,
Hauser
A. E.
,
Hoyer
B. F.
,
Mei
H.
,
Radbruch
A.
.
2011
.
Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.
Nat. Rev. Rheumatol.
7
:
170
178
.
79
Zhang
J.
,
Jima
D. D.
,
Jacobs
C.
,
Fischer
R.
,
Gottwein
E.
,
Huang
G.
,
Lugar
P. L.
,
Lagoo
A. S.
,
Rizzieri
D. A.
,
Friedman
D. R.
, et al
.
2009
.
Patterns of microRNA expression characterize stages of human B-cell differentiation.
Blood
113
:
4586
4594
.
80
Zhu
S.
,
Pan
W.
,
Song
X.
,
Liu
Y.
,
Shao
X.
,
Tang
Y.
,
Liang
D.
,
He
D.
,
Wang
H.
,
Liu
W.
, et al
.
2012
.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α.
Nat. Med.
18
:
1077
1086
.
81
Chang
P. V.
,
Hao
L.
,
Offermanns
S.
,
Medzhitov
R.
.
2014
.
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition.
Proc. Natl. Acad. Sci. USA
111
:
2247
2252
.
82
Singh
N.
,
Gurav
A.
,
Sivaprakasam
S.
,
Brady
E.
,
Padia
R.
,
Shi
H.
,
Thangaraju
M.
,
Prasad
P. D.
,
Manicassamy
S.
,
Munn
D. H.
, et al
.
2014
.
Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis.
Immunity
40
:
128
139
.
83
Cerutti
A.
2008
.
The regulation of IgA class switching.
Nat. Rev. Immunol.
8
:
421
434
.
84
Cerutti
A.
,
Chen
K.
,
Chorny
A.
.
2011
.
Immunoglobulin responses at the mucosal interface.
Annu. Rev. Immunol.
29
:
273
293
.
85
Takai
A.
,
Marusawa
H.
,
Minaki
Y.
,
Watanabe
T.
,
Nakase
H.
,
Kinoshita
K.
,
Tsujimoto
G.
,
Chiba
T.
.
2012
.
Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation.
Oncogene
31
:
1733
1742
.
86
Gonçalves
P.
,
Martel
F.
.
2013
.
Butyrate and colorectal cancer: the role of butyrate transport.
Curr. Drug Metab.
14
:
994
1008
.
87
Trompette
A.
,
Gollwitzer
E. S.
,
Yadava
K.
,
Sichelstiel
A. K.
,
Sprenger
N.
,
Ngom-Bru
C.
,
Blanchard
C.
,
Junt
T.
,
Nicod
L. P.
,
Harris
N. L.
,
Marsland
B. J.
.
2014
.
Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis.
Nat. Med.
20
:
159
166
.
88
Dorrestein
P. C.
,
Mazmanian
S. K.
,
Knight
R.
.
2014
.
Finding the missing links among metabolites, microbes, and the host.
Immunity
40
:
824
832
.
89
Thorburn
A. N.
,
Macia
L.
,
Mackay
C. R.
.
2014
.
Diet, metabolites, and “western-lifestyle” inflammatory diseases.
Immunity
40
:
833
842
.
90
Hill
D. A.
,
Siracusa
M. C.
,
Abt
M. C.
,
Kim
B. S.
,
Kobuley
D.
,
Kubo
M.
,
Kambayashi
T.
,
Larosa
D. F.
,
Renner
E. D.
,
Orange
J. S.
, et al
.
2012
.
Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation.
Nat. Med.
18
:
538
546
.
91
Cahenzli
J.
,
Köller
Y.
,
Wyss
M.
,
Geuking
M. B.
,
McCoy
K. D.
.
2013
.
Intestinal microbial diversity during early-life colonization shapes long-term IgE levels.
Cell Host Microbe
14
:
559
570
.

The authors have no financial conflicts of interest.

Supplementary data